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ABSTRACT
DECONVOLUTING THE ENGINEERING AND ASSEMBLY
INSTRUCTIONS FOR COMPLEX III ACTIVITY
Sarah Chobot Hokanson

P. Leslie Dutton, Ph.D., FRS
In respiratory systems, membrane-bound Complex III catalyzes the oxidation of
ubiquinone and the reduction of a soluble cytochrome with the bioenergetic formation of
a transmembrane proton gradient (∆µH+). Complex III turnover is initiated by a unique
two electron oxidation of ubiquinone at the Qo site; one electron is delivered to a high
potential chain containing an iron-sulfur cluster, cytochrome c1 and cytochrome c2, and a
second electron is transferred to a low potential chain that terminates at the Qi site. All
Complex III electron tunneling reactions are reversible, and a critical part of Complex III
maintaining productive turnover is its suppression of energy-wasting reverse electron
transfer reactions. The key to uncovering the controversial mechanism of Qo oxidation is
determining how Complex III is regulated such that productive electron-transfer steps
overwhelm unproductive steps.
This thesis focuses on understanding the structural and biochemical tolerances of
the redox cofactors in Complex III and applying that knowledge towards the design of a
simple, but robust, amphiphilic maquette that is capable of transmembrane proton and
electron transfer. In chapter two, kinetic studies of heme c1 mutants reveal that R.
sphaeroides Complex III is engineered to withstand large changes in heme c1 active site
residues while still preserving heme c1 midpoint potential and enzyme turnover. In
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chapter three, the maquette approach was applied toward developing a simple model
protein (AP6) that retained the minimum engineering requirements for Complex III
electron and proton transfer reactions but lacked the complexity found in the natural
system. The AP6 peptide assembles as a four-α-‐helix bundle protein and can potentially
bind up to six hemes tightly across a membrane interface. Chapter four demonstrates that
AP6 successfully performs quinol-cytochrome c oxidoreductase activity in hundreds of
milliseconds. AP6 is the first example of a synthetic enzyme capable of near-natural
turnover rates. Chapter five focuses on defining the thermodynamic limit for maquette
activity. This work supports the further development of simple model proteins to study
aspects of Complex III mechanism.
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Chapter 1: Introduction

Thirty years ago, Peter Mitchell won the Nobel Prize for the development of the Q-cycle
model that advanced our understanding of Complex III. While the principle tenets of his
Q-cycle still hold true today, Mitchell did not explain the specific mechanism that allows
the Qo site to perform this Q-cycle efficiently without undue energy loss. Though much
speculation on Qo site mode of molecular action and regulation has been introduced over
the thirty years after Mitchell collected his Prize, no single mechanism has been
universally accepted. In this introductory chapter, the history behind the search for the
true Qo mechanism is discussed, and the current models for the mechanism of Complex
III electron tunneling reactions are examined. Portions of this chapter have been included
in the following references [1, 3, 4] and are reprinted with permission from SpringerLink,
the Journal of Bioenergetics and Biomembranes [3, 4], and Biochimica et Biophysica
Acta – Bioenergetics [1].
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Figure 1.1: A contemporary view of the mitochondrial respiratory chain, which
contains (left to right) Complex I, Complex II, Complex III, cytochrome c, and
Complex IV. Blue arrows indicate electron tunneling pathways, red arrows indicate
the direction of proton translocation, black arrows indicate the arrival/placement of
substrate molecules, and green arrows indicate the position and movement of quinone
molecules. This figure was modified from a figure presented in Biochimica et
Biophysica Acta – Bioenergetics [1].
	
  

	
  

1.1 A summary of mitochondrial respiration
We now mostly understand the basic electron tunneling reactions (Figure 1.1 blue
arrows) that connect the complexes within the mitochondrial respiratory chain together.
In Complexes I and II, flavin-containing nicotinamide adenine dinucleotide (NADH) and
succinate dehydrogenase sites are connected via ubiquinone sites in the membrane
domain. These sites collect single electrons of the tunneling chains into pairs for two
electron and two proton quinone oxidation-reduction before exchanging with a
membranous quinone pool.

Complex III interacts with the quinone pool via two

ubiquinone oxidation-reduction sites, Qo and Qi, Once reduced Qo is bound to Complex
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III, one electron reduces cytochrome c1 while the other electron equivalent passes through
two b-type hemes and reduces a quinone molecule at the Qi site.

In the terminal

Complex IV, cytochrome c electron transfer leads to dioxygen reduction.
Although the overall stoichiometries of redox-linked proton exchange (red
arrows, Figure 1.1) are known, the basics these are coupled to the electron tunneling
reactions of ubiquinone (Complexes I, II and III) or dioxygen (Complex IV) that generate
the transmembrane electrochemical proton gradient (ΔµH+) remain undefined and
controversial.

The most information is known about Complex IV, as the key

intermediate redox states of the stepwise four-electron reduction of dioxygen have been
resolved structurally [7, 8] and spectroscopically [9-11].

However, the molecular

mechanism of its driven proton pump remains to be determined. Information about the
operation of the Qs site in Complex II is limited [12]; most experiments have been
focused on the redox chemistry of its FeS clusters [13, 14] and heme b [15-17] instead.
Incomplete structural information available for Complex I has limited the resolution of its
proton pumping mechanism, though several hypotheses exist in the literature at present
[18-23]. One of the most controversial questions left unanswered about the operation of
the mitochondrial respiratory chain is the molecular mechanism of ubiquinone oxidationreduction, proton exchange and energy coupling at the Qo site in Complex III. In sharp
contrast to Complex IV, the redox intermediate states of Qo have proven difficult to
access, lack clear spectroscopic signatures, and remain highly uncertain.

1.2 Redox cofactors in the mitochondrial respiratory chain
Energy obtained by electron transfer through the mitochondrial respiratory chain
is also used to pump protons from the mitochondrial matrix into the intermembrane
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space, creating an electrochemical proton gradient across the mitochondrial inner
membrane (ΔµH+). This electrochemical proton gradient allows adenosine triphosphate
(ATP) synthase to use the flow of protons to generate ATP from adenosine diphosphate
(ADP) and inorganic phosphate. In the absence of ADP, protons cannot flow back to the
matrix, and the pH and electrical gradients are at maximum. As respiration with outward
proton pumping proceeds, the free energy change for proton expulsion increases and
approaches the magnitude of that for electron transfer.

When the coupled reaction

becomes non-spontaneous, respiration stops, and this state is called a static head. The
formation of reactive oxygen species is supported by static head conditions in the
mitochondrial respiratory chain [24].
There are many different types of redox-active cofactors responsible for protoncoupled electron transfer reactions within the mitochondrial respiratory chain. These
cofactors span a wide range of midpoint potentials, and are linked together in long chains
that extend over long distances within these proteins to link together remote catalytic
sites.
1.2.1 Quinones. There are two main types of quinones found in biological
systems – benzoquinones and naphthoquinones.

Ubiquinone is a lipid-soluble

benzoquinone with a long isoprenoid side chain. Plastoquinone and menaquinone are
ubiquinone analogs found in plant chloroplasts and bacteria respectively. Quinones can
participate in one or two electron transfer processes coupled to the transport of one or two
protons. Therefore, there are three different redox states that exist for quinone cofactors –
quinone (oxidized), semiquinone (half reduced), quinol (fully reduced) – and three
corresponding protonation states for each redox state.
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All nine quinone states are

Figure 1.2: Thermodynamic box of nine possible ubiquinone redox/protonation states
(ubiquinone is drawn here without its isoprenoid side chain). Shown in red are the
quinone states that have been observed in biological systems, while shown in black are
thermodynamically unfavored states. This figure was modified from a similar figure
shown in the thesis of Bruce Lichtenstein [2].
	
  

	
  

depicted in Figure 1.2, though only the states depicted in red have been observed in
biology.
Quinones are regulated in membrane complexes through the stability of their
semiquinone redox state, which is related to the redox potential difference between their
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QH2/SQ and SQ/Q couples.

The stable equilibrium constant for the intermediate

semiquinone state at complete redox equilibrium is referred to as a semiquinone stability
constant, or Kstab:

Equation 1.1
Log Kstab values greater than one mean that the semiquinone is a dominant species
during a redox titration, while log Kstab < -4 means that the semiquinone will be barely
observable spectroscopically, if at all.
1.2.2 Hemes. Hemes consist of an iron ion coordinated to a large heterocyclic
organic ring called a porphyrin. The most common porphyrin scaffold in biology is
protoporphyrin IX (PPIX), otherwise known as heme b. The heme b biosynthesis
pathway is highly conserved across biological organisms, and is initiated in the
mitochondrion by the synthesis of D-aminolevulinic acid (dALA) from glycine and
succinyl-CoA.
In addition to heme b, there are two other main forms of hemes found in the
mitochondrial respiratory chain. c-type hemes contain a modified FePPIX where the two
vinyl side chains are uniquely covalently attached to cysteine thiol residues within the
protein. In the mitochrondrial respiratory chain, heme c is most notably found in the
cytochrome c1 subunit of Complex III and its redox partner, cytochrome c2. Heme a is
found in Complex IV, and is also synthesized through modification of FePPIX. The C-8
methyl group of FePPIX is oxidized into a formyl group and the vinyl group on C-2 is
converted into a hydroxyethylfarnesyl side chain.
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1.2.3 NAD+ / NADP+. Nicotinamide adenine dinucleotide (NAD+) and its close
analog nicotinamide adenine dinucleotide phosphate (NADP+) consist of two nucleotides
joined by a pair of bridging phosphate groups. The plus sign in the abbreviations for
these cofactors does not indicate their net charge, but rather that the nicotinamide ring is
in its oxidized form with a positive charge on the nitrogen atom. Both cofactors undergo
reversible reduction of the nicotinamide ring.

As a substrate molecule undergoes

oxidation, the oxidized form of the nucleotide accepts a hydride ion (or the equivalent of
a proton and two electrons) and is transformed into the reduced form (NADH or
NADPH). More than 200 enzymes are known to catalyze reactions in which NAD+ (or
NADP+) accepts a hydride ion from a reduced substrate, or NADH (or NADPH) donates
a hydride ion to an oxidized substrate. In Complex I, hydride transfer from NADH to a
bound quinone cofactor initiates the proton pumping mechanism of the mitochondrial
respiratory chain.
1.2.4 FAD / FADH˙ / FADH2. Flavin adenine dinucleotide (FAD) consists of a
riboflavin moiety that is bound to the phosphate group of an ADP molecule. The fused
ring structure of the flavin also undergoes reversible reduction, accepting either one or
two electrons in the form of one or two hydrogen atoms (each atom is the equivalent of
one electron and one proton) from a reduced substrate. After one electron transfer
reaction, like quinones, FAD can form a semiquinone state. This semiquinone state also
has an equilibrium-based stability constant related to the two redox couples of the flavin
moiety.

FAD is covalently bound to Complex II, and is responsible for initiating

Complex II electron transfer via the oxidation of succinate to fumarate.
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1.2.5 FeS cluster. In FeS clusters, iron molecules are present in association with
inorganic sulfur atoms or with the sulfur atoms of cysteine residues, or both. There are
three main structural motifs of biological FeS clusters, though exceptions do exist in
hydrogenase enzyme families. The simplest FeS cluster is the [2Fe-2S] cluster, which is
comprised of two iron ions bridged by two sulfide ions and coordinated by four cysteinebased thiol ligands. [4Fe-4S] clusters feature four iron ions and four sulfide ions placed
at the vertices of a cubane-like structure. In these FeS clusters, the iron ions are typically
coordinated by cysteine thiol ligands. Finally, proteins also coordinate 3Fe-4S centers,
which feature one less iron ion than the more common [4Fe-4S] form. Three sulfide ions
bridge two iron ions each, while the fourth sulfide bridges three iron ions. Complexes I
and II each contain combinations of these different types of FeS clusters. Complex III
contains a variation of a [2Fe-2S] cluster, where two histidine residues, rather than two
cysteine thiol groups, coordinate one of the two iron atoms. This type of [2Fe-2S] cluster
is named for John Rieske, after the Complex III iron-sulfur protein (ISP) domain was
isolated in 1964 [25, 26].

1.3 Complex III – what we know
In 1976, Peter Mitchell developed the Q-cycle theory, which explained how the
proton coupled electron transfer of Complex III was driven by its ubiquinone cofactors
[27, 28].

According to Mitchell’s proposal, which also incorporated the previous

observation of “oxidant-induced reduction of cytochrome b” by Chance [29] and a
suggested role for semiquinone by Wikstrom and Berden [30], a reduced quinone
molecule at the interface between the high and low potential chains of Complex III
(bound at the Qo site) initiates a bifurcated electron transfer reaction upon its oxidation.
	
  

8	
  

One electron is accepted by the iron-sulfur cluster (FeS), and follows the c-chain via
cytochrome c1 to external c-type cytochromes (Figure 1.3). The other electron passes
through two b-type hemes and reduces a quinone molecule at the Qi site. This unique

	
  
Figure 1.3: Each panel represents a step in the electron and/or proton transfer process
of one complete Q-cycle (Complex III is represented here as a monomer for
simplicity). a) One reduced quinol molecule is delivered to the Qo site from the Qpool. b) The Qo site becomes oxidized, transferring two protons across the membrane
and distributing two electrons to the high and low potential chains of bc1. c) A proton
and electron are delivered to the Qi site, forming a stable semiquinone intermediate.
d) The Q-pool delivers another reduced quinol molecule to the Qo site to restart
Complex III turnover. e) The Qo site turns over again, delivering a second set of
electrons to the high potential c-chain and the low potential b-chain, as well as two
more protons across the membrane. f) Upon receiving an additional proton and an
electron from heme bH, the Qi semiquinone becomes fully reduced, and delivers a
reduced quinol back to the Qpool. The net result of this cycle is oxidation of one
quinol, reduction of two cytochromes c, two electrogenic transmembrane electron
transfers, uptake of two protons from one membrane face and delivery of 4 protons to
the other. Reprinted with permission from SpringerLink and the Journal of
Bioenergetics and Biomembranes [3].
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electron split sets into motion a quasi-equilibrium state of Complex III that balances the
redox potentials of the high potential c-chain and low potential b-chain evenly on either
side of the redox potential of the quinone pool. This quasi-equilibrium behavior shows
that Complex III catalysis is rapidly and readily reversible [6]. Collapse of this quasiequilibrium into complete equilibrium, in which all chains and pools reach the same
redox potential, takes place on a tens of seconds timescale and can be assisted by the
short-circuiting action of redox mediator dyes.
Under normal forward electron transfer conditions, the efficiency of Complex III
turnover is high, and deleterious short circuit or bypass reactions involving either Qo or
heme bL are minimal [31]. Short circuit reactions are defined as any electron transfer
reaction between two Complex III cofactors that results in an unproductive loss of energy
[6]. Alternatively, bypass reactions result when the electron transfer processes at the Qo
site are intercepted by an extraneous reagent, such as oxygen, which steals the electron
from Complex III and initiates harmful side reactions that produce reactive oxygen
species [32, 33].

In order for the Qo site to be efficient, these reactions must be

suppressed, even though the driving forces for these reactions are highly favorable.
Understanding Qo site engineering means understanding how electron transfer is
regulated such that productive electron-transfer steps overwhelm unproductive steps.
1.3.1 Considering Qo movement in its active site. Crystal structures have
failed to convincingly resolve oxidized or reduced quinone in the Qo site [34-36]; in fact,
the Qo site appears to be large enough to potentially accommodate two sequential
positions for a moving ubiquinone headgroup [24, 37], or conceivably bind multiple
ubiquinones at the same time [38-40]. However, we do know that whatever the specific

	
  

10	
  

electron tunneling distances between Qo-FeS and Qo-bL are, the distances in Complex III
in general are engineered to allow for millisecond Qo oxidation and avoid short-circuit
reactions that would be a danger even to a concerted mechanistic model, such as direct
electron transfer between FeS and bL.

	
  
Figure 1.4 (top panel): Crystal structure of FeS-Qo-bL active sites, drawn from PDB
file 1PPJ [5]. Heme bL is depicted in red, the FeS cluster is drawn in orange, and two
Qo site inhibitors myxothiazol (yellow) and stigmatellin (green) are shown bound in
the Qo site. Distances between the cofactors were calculated using Pymol, where 23
Å represents the distance between the FeS cluster and bL , 7 and 11 Å represent
stigmatellin distances from the FeS cluster and bL respectively, and 13 and 6 Å
represent myxothaizol distances from the FeS cluster and bL respectively. (bottom
panel) The halftime of bL reduction (s-1) vs. Qo-FeS distance.
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Shown in Figure 1.4 are two Qo inhibitor molecules, myxothiazol (yellow) and
stigmatellin (green), bound at the Qo site, with their respective distances to the other
cofactors measured using Pymol software [41]. Myxothiazol binds closer to bL in the Qo
niche than stigmatellin does, and could still allow some quinone to approach the Qo
pocket distally. This could explain the observations in the literature that myxothiazol has
no effect on the semiquinone signal attributed to Qo [42], and permits considerably more
superoxide production by Complex III than stigmatellin [43, 44].
As described in the Appendix, the Dutton laboratory has developed an electron
transfer rate expression that offers a simple way to examine parameters that directly
relate to the oxidoreductase activity of a particular mitochondrial enzyme [1, 45, 46].
The Moser-Dutton equation defines the rate of electron transfer as a function of distance
(R), midpoint potential (included in ΔG°), reorganization energy (λ), and protein packing
density (ρ). Using this equation, a range of Qo-FeS distances can be considered to
determine the effect changing the location of Qo in its active site has on the rate of bL
reduction. Figure 1.4 depicts the halftime of heme bL reduction vs. Qo-FeS cluster
distance and demonstrates that millisecond bL reduction rates are maintained as long as
the Qo-FeS distance falls between 6 and 11 Å at pH 7. Though it is well-established that
the uphill electron tunneling step between reduced Qo and the FeS cluster is rate-limiting
as long as Qo falls within this 6-11 Å range [47], should Qo favor binding more closely
(within 4 Å) to the FeS cluster, Qo to bL electron tunneling becomes rate limiting and
slows bL reduction by two orders of magnitude. Likewise, should Qo bind closely to the
bL heme, Qo oxidation rates are limited by Qo-FeS cluster electron tunneling. This
general trend is upheld using equilibrium midpoint potentials at several different pH

	
  

12	
  

values, though the reaction rates for Qo oxidation increase as the pH becomes more
alkaline, increasing the range of FeS-Qo distances that will maintain millisecond
catalysis.
1.3.2 Previous models for Qo site mechanism. Without the direction of
structural information on Qo binding, a range of mechanistic models has emerged with no
real consensus as to which one is the most successful. The work of Osyczka et al.
prompted revision of all contemporary Q-cycle models in order to accommodate
suppression of unwanted short-circuits in a reversible, energy-coupling mechanism
evident in Complex III [6, 48]. However, it was made clear that models that are truly
concerted two-electron transfer reactions [6], with no detectable semiquinone
intermediate state on more than a femtoseconds timescale, were not prone to the same
kind of short circuit possibilities as sequential models that included a semiquinone
intermediate state [47, 49].

Therefore, all sequential mechanisms that exploit the

properties of a semiquinone intermediate [24, 48, 50-52], must be modified to include
effective gating mechanisms, sensitive to different combinations of redox states of the
FeS, Qo and heme bL redox partners, to promote productive catalysis and prevent
unproductive short-circuits.
While there are numerous ways that reversible Q-cycle models can be modified to
impede short circuits, Osyczka et. al. made it clear that a minimum of two gates or
barriers are mandatory to regulate Qo redox states. This model has been amplified by
Peter Rich, who introduced a double, “logic gated” electron transfer model for Qo site
electron transfer [52]. In short, this model suggests that reduced quinone is forbidden
from binding in the Qo site if FeS and heme bL are not both oxidized, and oxidized
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quinone is forbidden from binding if both of its redox partners are not reduced. This can,
in principle, be achieved by regulation of oxidized and reduced quinone binding by
manipulation of the conformations of Qo hydrogen bonding partners by the redox and
protonation states of heme bL and FeS (see also [6, 48].
Crofts et al. modified their sequential mechanism [53] to introduce more redoxstate sensitive gating to avoid short circuits [24, 50].

They propose that when a

semiquinone intermediate is formed, it can move closer to oxidized heme bL and
participate in productive electron transfer. However, when heme bL is reduced, there is a
Coulombic repulsion which keeps the semiquinone away from reduced heme bL, towards
the FeS end of the site, and inhibits the unproductive, and energetically favorable, shortcircuit reduction of semiquinone by heme bL. While in principle Coulombic interactions
could provide a redox-state sensitive gate to inhibit a short-circuit reaction, more than one
gate is needed. The Coloumbic push of semiquinone from reduced heme bL moves it
closer to FeS, which when oxidized, can accept an electron from the semiquinone in
another type of short circuit. A second gate for this type of model requires the FeS and
semiquinone to overcome their coulombic attraction and enter some sort of conformation
to prevent energetically favorable, but wasteful electron transfer. In addition, the site
must be designed to overcome a coulombic repulsion between semiquinone and reduced
FeS. This would allow a favorable interaction between semiquinone and reduced FeS,
fostering productive and rapid reverse reactions in which oxidized quinone is doubly
reduced by FeS and heme bL
1.3.3 Possibilities for Qo site thermodynamics. The thermodynamics of
concerted and sequential mechanisms are distinctly different even in wild-type Complex
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Figure 1.5: Electron transfer reaction energy surfaces for Qo site operation by
concerted and sequential mechanisms. Marcus-like parabolic potential surfaces are
shown for each redox state. In a concerted reaction (top), electron transfer to form a
semiquinone state (purple) takes more thermal energy than forming the two-electron
transition state. In a sequential mechanism (middle), electron transfer to form a
semiquinone intermediate state takes less energy than the simultaneous two electron
transfers, but leaves Complex III potentially exposed to highly exergonic short-circuit
reactions such as the one illustrated in the bottom panel. Reprinted with permission
from SpringerLink and the Journal of Bioenergetics and Biomembranes [3].
	
  
III. Figure 1.5 illustrates that the energetic landscape for a concerted mechanism at Qo
has an activation barrier that depends on both FeS and heme bL redox midpoint
potentials[3]. In this mechanism, the activation barrier for forming the semiquinone
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intermediate (purple curve) is significantly higher; normally semiquinone formation
would be minimal, but not impossible. In contrast, the sequential mechanism will have a
reduced quinone oxidation rate that depends on either the midpoint potential of the FeS
or the heme bL. Experimentally, changing the midpoint potential of the FeS often
changes the rate; however, changing the heme bL midpoint potential has proven more
difficult and the changes that have been made are modest. Thus, how or if the heme bL
midpoint potential affects the rate is still unclear.
The bottom panel of Figure 1.5 illustrates the energetic picture of one of the shortcircuit reactions [3]. The rapid reversibility of the reactions at the Qo site means reverse
electron transfer is on roughly the same timescale as the forward reaction, and will
reform the same amount of semiquinone that is formed by the initial electron transfer
between Qo and the FeS cluster. However, the short-circuit reduction of reoxidized FeS
is highly favorable and energetically disastrous; if Complex III is operating by a
sequential mechanism, redox-state activated gates must be present to avoid unproductive
short-circuit reactions.
1.3.4 Previous attempts to isolate SQo.

Direct observation of a Qo

semiquinone state has proven to be extremely controversial due to the limitations in
measuring such an unstable state.

In 1979, Takamiya and Dutton redox-poised R.

sphaeroides membranes and extracted the quinone cofactors to determine the amount of
quinone oxidized and the amount reduced as a function of poised redox potential [54].
From these experiments, they defined the size and redox potential of the quinone pool: 19
out of 25 quinones per reaction center had a midpoint potential at pH 7 of 90 mV. They
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also examined the redox-poised membranes for evidence of a Qo semiquinone by EPR
spectroscopy, but did not detect a clear signal.
de Vries et al. announced the trapping of a Qo semiquinone in mitochondrial
Complex III as a 2,3-dimercaptopropanol (BAL)-sensitive signal uncovered under nonequilibrium conditions [55]. BAL chelates heavy metals and is suggested to destroy the
Rieske FeS center, allowing for a direct probe of the Qo site. Compared with the
antimycin-sensitive semiquinone signal discovered at Qi (g = 2.005, 10 G wide) [56], the
signal attributed to Qo in these experiments was narrower (8.8 G), had a slightly different
g value (2.006), and required less power to saturate. Since this signal was obtained using
non-equilibrium methods, the redox midpoint potential of the semiquinone couples could
not be determined. However, Junemann et al. revisited these experiments and revealed
that de Vries’s semiquinone signal was insensitive to a more modern collection of Qo site
inhibitor compounds, such as myxothiazol, MOA-stilbene, and stigmatellin [57].
Therefore, based upon this evidence, it remains unlikely the data published by de Vries et
al. was indicative of a Qo semiquinone state.
In recent years, two new EPR-based approaches emerged and revealed
semiquinone signals that were sensitive to stigmatellin, a tight binding Qo site inhibitor.
The first approach was explored by Cape et al. using anaerobic freeze-quenching
techniques after rapid mixing of antimycin-inhibited Complex III isolated from R.
capsulatus with decylubiquinone in the Qo active site [32]. This stigmatellin-sensitive
signal had a g-value of 2.0054 with a 11.9 G line width. Although this signal does appear
at or near the Qo site, it does not appear to have a clear magnetic interaction with the
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Rieske FeS cluster, raising questions about whether or not it is representative of a true Qo
semiquinone intermediate.
The Dutton laboratory explored the second approach; their experiments used
light-activated photosynthetic membranes with heme(s) bL and/or heme c1 knocked out,
deliberately driving the thermodynamics of Qo to maximize semiquinone production
[42]. After a series of light flashes, the high potential c-chain became highly oxidized in
this system, stimulating the oxidation of Qo by the quinone pool and loading the low
potential b-chain with reducing equivalents. This experimental setup, where the high
potential chain is very oxidized, proved to be very favorable for stripping an electron
from a second quinol at Qo to form a semiquinone. The g-value of the signal observed
under these conditions was determined to be 2.0040 and the line width was 11.7 G.
Because the stoichiometry of the redox components involved in the pseudo-equilibrium
between the b- and c-chains and the quinone pool was known, the split between the redox
couples for this quinone species was estimated to be approximately 880 mV, with the
QH2/SQ couple ~410 mV at pH 9. Therefore, from this data the effective stability
constant for Qo was estimated to be 10-15. However, this data was obtained using
chromatophore membranes with massive mutational changes (cofactor knockouts),
causing many in the field to argue that this signal, even if it was attributable to a Qo
semiquinone, was not indicative of a mechanistic state that could be observed in wildtype chromatophores.
Even though an EPR signature attributed to a Qo semiquinone has been
experimentally isolated and characterized, it is not yet clear if this is a legitimate,
transient mechanistic intermediate, or a side reaction forced into existence by
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experimental design. Therefore, it is still too soon to reject the possibility that the normal
Qo site mechanism is concerted, with the transfer of both electrons occurring in a very
short interval, leaving no time for an oxidized quinone to relax into any intermediate
state.
1.3.5 Complex III activity is unaffected by Qo binding site mutations. The
Qo site mechanism is also surprisingly resilient to mutational modifications at the Qo
site. Though the mostly conserved glutamate (E) of the Qo active site PEWY sequence is
often given a carefully orchestrated role controlling the proton transfer reactions of QH2
oxidation at the Qo site [24, 50], replacement of the glutamate group with non-polar or
even basic groups had almost no effect on any of the equilibrium properties of the Qo site
or its redox partners [51]. As the Qo site appears to have residue redundancy that
compensates for mutagenic changes easily, a specific network of protons within the
active site may not be necessary for preserving productive Qo site electron tunneling.
Instead, the tunneling network itself must be designed to raise barriers that suppress
unwanted short circuit reactions.
1.3.6 Redox properties of the quinone sites in Complex III. The bifurcated
electron transfer that occurs within Complex III is completely dependent upon its ability
to modify the redox environment of the ubiquinone pool at each of its quinone binding
sites, Qo and Qi. The environment of the Qi binding site forces the quinone redox
couples to be very similar. The redox couples and stability constant for Qi have been
measured (log Kstab is -2.3 at neutral pH) using EPR spectroscopy, and under mildly
alkaline conditions, the redox midpoint potentials of the oxidized quinone, semiquinone,
and fully reduced quinol can reach equilibrium at equal one third concentrations. At Qo,
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the first electron is removed from the reduced quinol at a relatively oxidizing midpoint
potential to head down the high potential c-chain, while the second electron is removed at
a relatively reducing midpoint potential and is transferred to the low potential b-chain.
Therefore, unlike Qi, the redox couples at Qo have a very large difference in midpoint
potential, and a very low Kstab value.
As shown in figure 1.6, there are eight possible combinations of redox states for
Qo and its redox partners, heme bL and FeS. Half of these states are equilibrium states
readily achieved by simple redox poising (shown in black), and half are non-equilibrium
states have yet to be experimentally characterized (shown in red and green). The green
states are particularly important since they are the enzyme-substrate and enzyme-product

	
  
Figure 1.6: Eight possible redox state combinations for the Qo site and its electron
transfer partners, FeS and heme bL. Equilibrium states are shown in black, productive
transient intermediates are shown in green, and non-physiological quasi-equilibrium
states are shown in red. Solid lines indicate closed gates, and solid lines with a break
in the middle indicate open gates for electron transfer. Dashed lines indicate that a
gating mechanism is optional for this electron transfer. Reprinted with permission
from SpringerLink and the Journal of Bioenergetics and Biomembranes [3].
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states immediate to physiologically productive quinone oxidation- and reduction-coupled
energy transduction at the Qo site, while the states shown in red are subject to shortcircuit reactions that are high in driving force and physiologically unproductive.
Assuming a sequential-gated Qo site mechanism in this model, the gates controlling
semiquinone activity must be open so that catalysis can occur in the green states, while
the gates are closed in the red states in order to protect Complex III from short circuiting.
1.3.7 Redox properties of other Complex III cofactors. Understanding the
engineering design of Complex III and the operating limits of failure of the Q-cycle
requires an understanding of the redox properties of each redox-active component. The
redox properties of the cofactors in Complex III are well-described by redox titrations
performed across a wide range of pH values, as shown in Figure 1.7 [4]. The FeS cluster
has a pKox near neutral pH in both R. capsulatus and R.sphaeroides. Cytochrome c1 has
pKox and pKred values close to one another near neutral pH, and a weak pH dependency
(much less than 1 H+ / 1 e-). Previous measurements of the Qpool size and redox
properties are included on the left graph as a green dashed line [54], and Qi redox
properties were also previously measured under conditions where its semiquinone
species is readily accessible by EPR measurements [58].
The Dutton [4] and Crofts [50] laboratories have measured redox prorperties of
the b-hemes in recent years. Original redox titrations of the b-hemes revealed three redox
active species [59], which are now resolved in Figure 1.7 as bL and two different forms
of bH - bH

high

and bH

low

.

Heme bL displays a strong coupling to protons at acidic pH

values, and is pH independent at pH values more alkaline than its pKred (pH ~ 8.5).
These redox properties are unchanged in the presence of the Qi inhibitor antimycin. The
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Figure 1.7: Redox midpoint potentials of the components of Complex III in two
different species of photosynthetic bacteria as a function of pH, as determined
experimentally by Haibo Zhang. Reprinted with permission from SpringerLink and
the Journal of Bioenergetics and Biomembranes [4].
	
  

	
  

redox behavior of bH is directly coupled to the redox state of Qi, and is also altered when
antimycin is bound to the Qi site. 80% of heme bH centers are in the low potential form
at acidic pH values, though this number is reduced to 55% at alkaline pH values [4].

1.4 Developing a simple tunneling view of Complex III activity
The redox midpoint potentials and electron tunneling distances of the cofactors in
Complex III were inputted into the Moser-Dutton equation to calculate ket. These rates
are used to present an an elementary view of Complex III electron tunneling that is
expanded upon experimentally in chapter two.
1.4.1 A single turnover view of Complex III electron tunneling. Figure 1.8
shows a single, two electron turnover of Complex III when all of its redox components
are oxidized except for the Qo site, with its measured 10-15 Kstab constant [42] providing
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Figure 1.8: Electron tunneling calculations for Complex III. Shown on the left (A, C,
E) are rate calculations that assume that Complex III is functional as a monomer, and
shown on the right (B, D, F) are those for a functional dimer. Dashed lines in the
right-hand side graphs represent the redox centers in the second half of the dimer
introduced into the calculations. (A and D) All redox centers considered. (B and E)
Calculating all centers except Qi, which has been effectively “inhibited” by extending
the electron transfer distance to 50 Å. C and F) Considering site directed mutants
where heme bH is not incorporated [6]. Figure modified from data presented in
Biochimica et Biophysica Acta – Bioenergetics [1].
	
  
for millisecond catalysis of quinone oxidation. FeS is modeled as moving between two
sites, distal and proximal to the Qo site with a rate of about 105 s-1 [60]. Heme bL is only
transiently reduced as the electron comes to reside on heme bH and Qi. Also, when the

	
  

23	
  

electron can get as far as Qi, short-circuit reactions through reverse reactions and a Qo
semiquinone are slowed to a minutes timescale.
These calculations can be modified to include inhibitors or mutations that limit
Complex III turnover. For example, the addition of antimycin at the Qi site or bH
knockout mutations can be considered in our system of rate equations.

Heme bH

reduction is dominant in the presence of antimycin, with short-circuits still taking place
relatively slowly on a tens of seconds timescale (under non-membrane energized
conditions), representing what is observed under single turnover flash experiments.
However, when heme bH is knocked out, the electron cannot escape from bL and is prone
to millisecond short-circuit reactions that are comparable to the rate of catalysis. Because
rapid short-circuit reactions are not observed experimentally in these knockouts, the
redox couples of Qo (and therefore, its stability constant), must be modulated in some
way to allow catalysis in certain redox states while making the semiquinone (and
therefore, short-circuit reactions) inaccessible in others.
Structurally, Complex III is a dimer, but whether or not it acts as a functional
dimer remains controversial. We can compare Complex III as a functional monomer or
dimer using the Moser-Dutton equation.

With an edge-to-edge spacing of 14.7 Å

between the two heme bL cofactors, functionally significant electron tunneling between
the two halves of the dimer could take place on a reasonable timescale. This is shown in
the right panels of Figure 1.8, mirroring the conditions described above.

Redox

equilibration of the low potential chains is shown to take place on a seconds timescale,
depending upon the presence of Qi. Short-circuit reactions occur in both halves of the
dimer, even though reduced quinone has only been introduced at one of the Qo sites.

	
  

24	
  

However, with the same fixed stability constant, of 10-15, the heme b knockout allows the
electron to linger on bL, with cross-dimer redox equilibration occurring on a millisecond
timescale. Therefore, the electron tunneling contact between both halves of the dimer is
occurs on the same timescale as catalysis, indicating that Complex III has effectively
increased the concentration of active Qo sites available when the complex is partially
reduced.

1.5 Finding new ways to study an old problem
It has been decades since Peter Mitchell developed the Q-cycle mechanism with
little resolved about the mechanism of Qo turnover in Complex III. In order to address
these unanswered questions, the field of bioenergetics must develop a fresh perspective
and new experimental techniques. In chapter two, R. sphaeroides Complex III proteins
with modifications to their heme c1 are studied to understand how Complex III redox
reactions within the high and low potential chains are interconnected.
This thesis also applies the principles of de novo protein design towards
developing a new model system to study Complex III turnover. In chapter three, the
development and characterization of the first functional amphiphilic maquette, AP6, is
presented.

AP6 extracts the basic engineering requirements from the b-subunit of

Complex III to perform proton-coupled electron transfer across a membrane interface.
In chapter four, AP6 enzymatic function is quantified using standard Complex III activity
assays, and AP6 is revealed as the first maquette to achieve activity within two orders of
magnitude of a natural protein system. Manipulating the thermodynamics of the ratelimiting quinol to heme electron transfer step in this maquette system is explored in
chapter five. Finally, chapter six will conclude with the development of a simple model
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for Complex III that can be applied by the field of bioenergetics to study specific Qo
redox states.
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Chapter 2: Mutations to heme c1 binding site
residues reveal R. sphaeroides Complex III
activity is robust

It is becoming increasingly clear that electron transfer chains in natural proteins are not
finely tuned, but robustly designed to transfer electrons between catalytic sites and
survive the many obstacles of mutational change during evolution and natural selection.
In this chapter, mutational work at heme c1 has revealed that the reversible electron
transfer chain in R. sphaeroides Complex III is engineered to withstand large changes in
active site residues and midpoint potential to preserve turnover. The impact of altering
these motifs in R. sphaeroides was tested as a means to explain how heme c1 can
maintain its function in response to massive changes in R. sphaeroides ligation, while the
midpoint potential of R. capsulatus c1 cannot avoid collapsing to a dysfunctional level.
This work is part of a first-author manuscript in preparation to Biochemistry [1].
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2.1 Introduction
A critical part of maintaining the productive energy-conversion observed in
Complex III is the protection against electronic and protonic short circuits between
reactive intermediates subsequent to charge separation [3, 4].

By promoting

macroscopically reversible energy coupling, Complex III has several unproductive short
circuits to defend against within the Qo site, and cannot rely upon the high driving force
and practical irreversibility used by photosynthetic reaction centers as a defense.
2.1.1
complicated

Mutations at the heme c1 binding site.
Qo

bifurcation

electron

transfer

reaction

Though the seemingly
should

have

specific

thermodynamic requirements for the rest of the redox cofactors in Complex III in order to
avoid these short circuit reactions, surprisingly, Complex III turnover is rarely affected by
substantial midpoint potential changes within the high potential chain. While the CXXCH
motif found in R. sphaeroides is the consensus motif for high potential class I c-type
cytochromes, previous work has demonstrated that the heme c1 found in this system is
very tolerable to changes in its sixth axial ligand methionine [5]. This tolerance was
described as a gradual decrease in the midpoint potential of heme c1 as the methionine
residue is varied, with only a M185H mutant rendering the midpoint potential too low for
Complex III to remain functional.
Both R. capsulatus and R. sphaeroides c1 subunits contain a disulfide-secured
loop near the heme binding site that has been identified to support high c1 midpoint
potentials [2, 5, 6]. However, surprisingly, the threshold for making changes to the c1
sixth ligand in R. capsulatus is significantly lower than that of R. sphaeroides. It has
been proposed that the β−branched amino acid that directly precedes the heme ligating
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position in R. sphaeroides increases both solvent inaccessibility and protein packing
within the c1 subunit and helps to maintain a higher c1 midpoint potential even after
changes to the methionine residue are introduced. In fact, adding a β-branched amino
acid motif to R. capsulatus can repair incompetent midpoint potentials caused by
breaking the disulfide loop [6].
	
  

2.1.2 Inhibition of heme c1. Adding inhibitors to the quinone sites has been

used to isolate electron transfer reactions in the low-potential chain of Complex III and
control the flow of electrons. Stigmatellin [7, 8] and myxothiazol [9] can be added to
inhibit Qo oxidation, and antimycin inhibits Qi reduction [10]. However, these inhibitors
do block Qo and Qi from their active sites, making it impossible to isolate and describe
specific quinone catalytic events when inihibitors are bound.
	
  

Reversible inhibition of the hemes in Complex III would allow the isolation of

sequential electron transfers to be extended to the high-potential chain of Complex III
without sabotaging Qo site oxidation. Photo-dissociable small ligands, such as carbon
monoxide (CO) are ideal inhibitors of heme c1 because their dissociation rate from heme
c1 would be on the same timescale as enzyme turnover, enabling normal electron transfer
between the FeS cluster and heme c1. Additionally, the formation of a heme c1-CO
complex would provide a unique experimental opportunity to light-activate Complex III
in the absence of other chromatophore proteins, such as the reaction center. This would
simplify current light-activation experiments that involve chromatophore membranes that
contain several redox proteins (that can have overlapping spectral properties). Though a
heme c1-CO complex has never been formed in wild type Complex III, heme c1 has
proven to be amendable to ligation with other small molecules. Oxidized heme c1 in R.
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capsulatus Complex III has been demonstrated to reversibly bind cyanide with high
affinity and shift the heme midpoint potential dramatically [11].

2.2 Materials and Methods
2.2.1 Bacterial strains and growth. Mutations to Complex III heme c1 binding
site residues were constructed by Haibo Zhang using the Quikchange site-directed
mutagenesis system (Stratagene) as described previously [12].

These mutants were

stored as glycerol stocks at -80 º C.
50 µL of R. sphaeroides glycerol stocks were plated on agar plates with Sistrom’s
Minimal Media A and 10 µM tetracycline. Plates were incubated for 2 days at 37 º C. 25
mL of autoclaved Sistrom’s Minimal Media A with tetracycline added was inoculated
with a single colony from the plate, and these flasks were agitated in the dark at 37 º C
and 200 rpm overnight. 10 mL of this culture were transferred to 1 L of growth media
and agitated in the dark for an additional day at 37 º C and 200 rpm.
2.2.2 Chromatophore membrane / protein purification. Growth media was
centrifuged at 5000 rpm for 30 minutes and cell pellets were collected. Cell pellets were
resuspended in 90 mL of equilibration buffer (100 mM NaCl, 50 mM Tris pH 8, 20%
glycerol). Phenylmethanesulfonylfluoride (PMSF) (Sigma) was added to the solution at a
final concentration of 2 µM, and the solution was French pressed to break the cell
membranes. Cells were centrifuged at 10,000 rpm for 45 minutes, and the supernatant
was collected for ultracentrifugation. The solution was spun at 45,000 rpm for 2 hours,
and the chromatophore pellet was collected and resuspended in 25 mL of equilibration
buffer for purification.
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Complex III proteins were purified from chromatophore membranes using a
BioGel A DEAE ion-exchange column (Bio-Rad). The column was equilibrated with
five column volumes of equilibration buffer and 10 mL of the protein sample was loaded
onto the column. The column was washed with two column volumes of equilibration
buffer and then a 200 mL salt gradient of 150 mM to 600 mM NaCl was used to elute
Complex III (buffers also contained 50 mM Tris pH 8 and 20% glycerol). Complex III
eluted between 375 – 400 mM NaCl. The fractions that contained Complex III were
pooled and dialyzed against a low salt buffer overnight and then concentrated to 5 mL of
purified protein. Reduced minus oxidized UV-visible difference absorption spectra
(Figure 2.1) were collected for each of the Complex III mutant proteins in this study.
2.2.3 Flash-induced single turnover kinetics. Flash-induced single-turnover
time-resolved kinetics were performed according to [13] using chromatophore
membranes and a double-wavelength spectrophotometer (Biomedical Instrumentation
	
  

	
  
Figure 2.1: Difference UV-visible absorption spectra of Complex III wild type and
heme c1 mutant proteins. Both spectra are the difference in absorption between
reduced Complex III and oxidized (using potassium ferricyanide). The dotted line
represents the samples reduced with ascorbate and the solid line represents samples
reduced with dithionite.
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Group, University of Pennsylvania, Philadelphia, PA) in the presence of 2.5 µM
valinomycin, 8 µM 2,3,5,6-tetramethyl phenylenediamine, 2.5 µM

phenazine

methosulphate, 2.5 µM phenazine ethosulfate, 6 µM 1,2 naphthoquinone, 6 µM 2hydroxy-1,4-naphthoquinone, 100 µM ferrocyanide and 70 µM benzyl viologen.
Transient cytochrome c re-reduction kinetics initiated by a short saturating flash (8 µs)
from a xenon lamp was followed at 552-540 nm. The concentration of antimycin,
myxothiazol and stigmatellin used were 5, 5 and 1 µM, respectively, and the ambient
potential was poised at 100 mV or 250 mV.
2.2.4 Redox titrations of heme c1 mutants. Equilibrium redox potentiometry
was used as a functional analysis of the oxidation and reduction of heme c1 [14]. Redox
titrations were performed in an anaerobic 1 mL cuvette (Starna Cells) equipped with a
silver / silver chloride and platinum combination electrode (Microelectrodes Inc.). All of
the potentials reported are in reference to the normal hydrogen electrode (NHE). The
reduction potential of the cuvette solution was adjusted by adding microliter aliquots of
freshly prepared solutions of either sodium dithionite (for reducing) or potassium
ferricyanide (for oxidizing). 20 µL of a stock solution containing the following redox
mediator dyes was also added to the solution (final concentrations reported): 2.5 µM
valinomycin, 8 µM 2,3,5,6-tetramethyl phenylenediamine, 2.5 µM

phenazine

methosulphate, 2.5 µM phenazine ethosulfate, 6 µM 1,2 naphthoquinone, 6 µM 2hydroxy-1,4-naphthoquinone, 100 µM ferrocyanide and 70 µM benzyl viologen. After
equilibration at each midpoint potential, the UV-visible spectrum of Complex III was
recorded, monitoring in particular the increase in the sharp α-band absorption at 550 nm
relative to a 540 nm reference wavelength.
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2.2.5 CO binding. 3 mL of 5 µM Complex III was added to a UV-visible quartz
cuvette and purged with argon. A concentrated dithionite solution was titrated in 1 µL at
a time until the protein was fully reduced (5-6 µL). 10 mL of CO gas was added to the
cuvette in the hood with a gas-tight syringe. The solution was monitored for up to two
hours to determine the extent of CO ligation, if any.
	
  

2.2.7 Reduction of decylubiquinone (DBH) substrate. Quinols were prepared

from the oxidized quinone using the method described by Peter Rich [15]. 0.25 g
decylubiquinone was dissolved in 50 mL diethyl ether and placed in a separatory funnel.
A solution of 1 g sodium dithionite in 50 mL water was added and the mixture was
shaken together. The quinone could be seen to initially increase in yellow color due to
semiquinone formation, but eventually became colorless as full reduction to quinol
occurred. The ethereal layer was shaken with a second 50 mL solution of sodium
dithionite to ensure completion of the reduction reaction. After removal of the dithionite
solution, the ethereal layer was washed twice with a saturated sodium chloride solution.
The ethereal layer containing quinol was then passed through 30 g anhydrous sodium
sulfate in a sintered glass funnel to remove any residual water, and the ethereal solution
was then dried down by rotovaporization at 25°C. The resulting white powder was
dissolved in an acidic ethanol solution (95% ethanol containing 10 mM hydrochloric
acid) and flash frozen in 500 mL aliquots.
2.2.8 Steady-state measurement of Complex III activity. Complex III activity
was measured using a standard assay developed by Trumpower et al [16]. A solution of
25 mM horse heart cytochrome c (Sigma) in redox buffer (50 mM potassium phosphate
and 100 mM potassium chloride at pH 8) and 10 µM decylubiquinone was incubated in a
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3 mL cuvette saturated with CO gas and stirred for one minute, after which CO-inhibited
Complex III was introduced into the cuvette in nanomolar concentrations (10-100 nM).
Using an extinction coefficient of 18.5 mM-1cm-1 for the 551 nm – 540 nm difference
absorption, cytochrome c reduction was monitored over time until the amount of
cytochrome c reduced reached a constant maximum.

2.3 Results
Sixth ligand mutagenesis of heme c1 caused electron tunneling at heme c1 to
become the rate limiting step in ubiquinone oxidation at the Qo site, establishing an
unfavorable redox equilibrium limit (three to four orders of magnitude) for Complex III
catalysis [5]. However, Complex III can tolerate a remarkably wide range of energy
barriers before turnover is halted, demonstrating that electron transfer reactions carried
out by long chains of cofactors are undeniably robust. This work explored whether the
disulfide loop residues found in the R. sphaeroides binding site are responsible for
stabilizing heme c1 midpoint potential. Mutations C145A, C169A, and C145AC169 did
not significantly impact Complex III activity or heme c1 midpoint potential, indicating
that these residues do not play an active role in stabilizing the midpoint potential of heme
c1 or modulating the thermodynamics of FeS cluster to heme c1 electron transfer. Table
2.1 summarizes the general characteristics for each of the disulfide mutants.
Representative flash kinetic traces and redox titrations for the mutant proteins are
reported as C145A data.
2.3.1 Flash kinetics of cytochrome c1 + cytochrome c2.

Using light-activated

chromatophores, the kinetics of specific redox reactions within Complex III can be
monitored following a short flash. The electrons delivered from the flash of light activate
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Table 2.1 Mutagenesis of cysteine residues in Rb. sphaeroides Complex III

Mutation
Wild type
C145A
C169A
C145A_C169A

Phenotype
(a)

Em7
(mV) (b)

bH reduction
rate (s-1) (c)

PS+
PS+
PS+
PS+

281
276
278
285

856
836
892
840

CO
binding

Reversion to Ps+(e)

(d)

+

N/A
N/A
N/A
N/A

(a) Ps+ and Ps- indicate photosynthetic competence and incompetence, respectively.
(b) Midpoint redox potential of cytochrome c1 in purified Complex III. (c) bH reduction
rates were determined by flash kinetics at the ambient potential of 100 mV at pH 7.0
by recording the absorbance changes at 560-570 nm, and fitting them to a single
exponential equation. (d) (+) and (-) indicate the ability of ferrocytochrome c1 in
isolated Complex III to binding carbon monoxide. (e) Spontaneous site suppressor
mutations in cytochrome c1 that restore photosynthetic activity of the cells.
the photosynthetic reaction center and go on to create the two substrates of Complex III,
oxidized cytochrome c2 and hydroquinone, within microseconds.
Figure 2.2 compares the flash-induced cytochrome c oxidation and re-reduction in
wild type and the C145A mutant measured under the conditions which preset cytochrome
c and FeS reduced and the quinone pool half-reduced before activation at 100 mV.
Kinetic traces without any inhibitor and with two potent Qo site inhibitors, myxothiazol
and stigmatellin, are shown. In all cases, the flash-induced cytochrome c oxidation
(cytochrome c1+c2, which is not resolved in the experiment) is rapid, with a time constant
beyond the resolution of the instrument.
The Qo site inhibitors provide a useful means of measuring the levels of different
phases of cytochrome reduction. Stigmatellin, which completely inhibits the Qo site
activity as well as fixes the FeS cluster in its b-position docked onto cytochrome b [17,
18], reveals the full level of oxidation of cytochrome c by flash activated reaction center
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Figure 2.2: Flash kinetics of heme bH and cytochrome c in chromatophores from wild
type Complex III and a C145A mutant. The ambient redox potential was poised at 100
mV at pH 7.0. The kinetics of the flash-induced cytochrome c were followed at 551540 nm (a, c), and the kinetics of the flash-induced heme bH were followed at 560-570
nm (b, d). The kinetic traces completed in the absence of inhibitors are shown in
black. The Qi site reaction was inhibited with antimycin (red), the Qo site was
inhibited with myxothiazol (blue), and in the control experiment, both Qi and Qo site
activity were inhibited with antimycin and stigmatellin (green).
	
  

	
  

(green traces in Figure 2.2). Myxothiazol, which also inhibits the Qo site but has no effect
on the FeS cluster movement, normally does not reveal the portion of cytochrome that
becomes rapidly reduced by pre-reduced FeS cluster. Thus, the offset in the amplitude of
cytochrome c oxidation with the stigmatellin and myxothiazol, seen clearly in wild-type
Complex III, is attributed to this initial phase of the cytochrome c re-reduction. C145A
displays very similar heme c1 kinetics as the wild-type Complex III protein. With no
inhibitors present, the re-reduction of heme c1 occurs at 143 s-1 in the C145A mutant, in
comparison to 167 s-1 for wild-type Complex III.
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2.3.2 Flash kinetics of heme bH. Using antimycin to completely inhibit electron
transfer at the Qi site [10] sets up a sensitive test for how changing the binding site
residues at heme c1 impact the rate of the Qo site bifurcation reaction and subsequent
redox equilibrium. Figures 2.2 and 2.3 shows the time-course of flash-induced heme bH
reduction in wild-type Complex III and the C145A mutant at two different driving force
conditions by changing the ambient redox potential prior to activation.
First, the redox potential of the chromatophores was poised at 100 mV, which
creates a state where the Q-pool is half-reduced and close to the potential of the Qo site
prior to the flash. In the presence of antimycin, the reduction of heme bH takes place on a
millisecond timescale in both wild type Complex III and the C145A mutant. In a second
experiment, chromatophores were poised at 250 mV prior to the flash. Under this

Figure 2.3: Flash kinetics of heme bH and cytochrome c in chromatophores from wild
type Complex III and a C145A mutant. The ambient redox potential was poised at 250
mV at pH 7.0. The kinetics of the flash-induced cytochrome c were followed at 551540 nm (a, c), and the kinetics of the flash-induced heme bH were followed at 560-570
nm (b, d). The kinetic traces completed in the absence of inhibitors are shown in
black. The Qi site reaction was inhibited with antimycin (red), the Qo site was
inhibited with myxothiazol (blue), and in the control experiment, both Qi and Qo site
activity were inhibited with antimycin and stigmatellin (green).
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condition, the Q-pool is fully oxidized and reduced quinone is only available after flash
activation of the reaction centers, diffusing through the Q-pool before binding to the Qo
site. For wild type, this diffusion is the rate-limiting step in the overall reaction at this
high redox potential, and heme bH reduction is slowed relative to when the system is
poised at lower redox potential. C145A actually demonstrates slightly faster bH reduction
kinetics under these condtions, with a rate of 119 s-1 compared to 77 s-1 in the wild-type
Complex III.
2.3.3 Heme c1 – CO. The ability of the mutant proteins to bind CO was tested to
determine if any of the heme ligands were disrupted by eliminating the disulfide bridge.

	
  
	
  
Figure 2.4: UV-visible spectra for reduced wild-type (a) and two cysteine mutant
proteins, C169A (b) and C145A (c), before (solid line) and after (dashed line) the
addition of CO to the cuvette.
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Figure 2.4 shows the UV-visible absorbance spectra for wild-type, C145A, and C169A
proteins before (solid line) and after (dashed line) treatment with CO. The difference
between the dithionite reduced + CO spectra minus the dithionite reduced spectra is
equivalent for all of the proteins, indicating that the ligands of heme c1 are not affected by
mutating the disulfide bridge residues. This is disappointing because of the experimental
advantages that could be gained from a light-activatable ligand in the high potential
chain, but not surprising given the mutants behaved so similarly to wild-type heme c1.
If left under a constant stream of CO gas for two or more hours, reduced wildtype Complex III does begin to demonstrate more significant spectral changes due to the
presence of CO in the cuvette. The Soret band blue shifts 5 nm from the reduced Soret
band found at 424 nm, and the characteristic b-heme α-band signature also begins to
decrease. These samples were tested for Complex III activity using the steady-state assay
developed by Trumpower et al [16] and were found to have diminished Complex III
activity even after the CO has been removed from the sample. Therefore, even on longer
timescales, it is not likely that wild-type heme c1 ligates a CO molecule to heme c1.
Instead, these changes could either be associated with a slow re-oxidation of the protein
or gradual destruction of the b-hemes by CO.

2.4 Discussion
2.4.1 Heme c1 binding motifs are not required for midpoint potential
stability. Not surprisingly, just as R. sphaeroides is more resilient to changes in its
disulfide loop region, it can also withstand mutations to its β-branched amino acid
without losing functionality. Single and double cysteine mutants that break the disulfide
bridge within the c1 heme-binding motif are still photosynthetically competent and retain
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Figure 2.5: Redox titrations of wild-type and C145A Complex III proteins in different
buffer conditions. These titrations are meant to reproduce the buffer conditons used
by Elberry et al [2]. The sample represented by the closed circles was prepared in the
same equilibration buffer used for purifying Complex III, and is the standard buffer
used by the Dutton laboratory. The open circles represent the same protein sample
with 50 mM histidine added to the redox buffer.
	
  
high c1 midpoint potentials (Table 2.1). Additionally, a double mutant that breaks the
disulfide loop and eliminates the β-branched isoleucine is also surprisingly still
physiologically competent [2].
Elberry et al. also reported experimental mutations in disulfide bridge residues
still resulted in Complex III functionality [2]; however, they report extremely low heme
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c1 midpoint potentials of approximately +50 mV that fall outside of the well-defined
thermodynamic threshold for heme c1 [5] If their midpoint potentials were correct,
Complex III would be unable to function because the thermodynamic barrier for FeS
cluster to heme c1 electron transfer would be insurmountable. This discrepancy can be
explained by their use of an imidazole buffer for protein purification and a histidine
buffer in their redox titration experiments. As shown in figure 2.5, the presence of
histidine and/or imidazole can lower midpoint potentials of heme cofactors by over 50
mV. Eliminating this artifact from their experiments would raise their reported midpoint
potential values to lie within the thermodynamic range previously defined for heme c1
and within the midpoint potentials determined in this chapter.

2.5 Conclusion
The specific engineering element of R. sphaeroides Complex III responsible for
the robustness of its heme c1 active site must include other interactions beyond those
provided by residues neighboring the active site, or may not be structurally related to the
heme c1 active site. It could be that electrostatic interactions with the FeS cluster (when it
is rotated proximal to the heme c1 active site) are enough to stabilize the midpoint
potential of R. sphaeroides heme c1 and preserve turnover of the high potential chain.
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Chapter 3: Design and characterization of an
amphiphilic maquette, AP6

The maquette approach uses simplified versions of natural proteins to investigate the
basic protein engineering necessary to reproduce functional elements of biological energy
transduction.

The first maquette family, which had a hydrophilic (HP) exterior,

established the design principles for iron-protoporphyrin IX (FePPIX) binding and
demonstrated proton coupling to oxidation/reduction. However, hydrophilic maquettes
cannot unravel design principles for protein assembly into membranes. Therefore, a
second maquette family was designed to be amphiphilic (AP), meaning it contains both
HP and lipophilic (LP) domains, and can assemble inside membranes. In this chapter, a
new member of the AP family of maquettes is fully characterized, AP6.

These

experiments reveal the full potential of AP6 to serve as a model system for studying
complicated transmembrane proteins, such as Complex III. The results contained within
this chapter are a part of two manuscripts in preparation [7, 8].
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3.1 Introduction
A century before this thesis work began, Emil Fischer won the Nobel Prize and
‘foresaw a time in which physiological chemistry will not only make greater use of
natural enzymes, but will actually resort to creating synthetic ones’ [9, 10]. Fischer’s
prediction was remarkably astute, as the field of de novo protein design has indeed
created robust protein-cofactor complexes that serve as simple models (or as the Dutton
laboratory has named them, maquettes) for much more complicated natural
oxidoreductases. Protein designers have established the principles for assembling watersoluble α-helical bundles [1, 11-16], transmembrane α-helical proteins [2, 17], and basic
β-sheet proteins [18, 19]; however, translating any particular protein function into a
successful synthetic protein construction remains challenging.
Part of what makes reproducing protein function difficult is an incomplete
understanding of the mechanisms of complicated oxidoreductases, such as Complex III.
These proteins have a built-in complexity arising from Darwin’s principle of multipleutility [20], which states that each amino acid in a protein is naturally selected for
multiple and overlapping roles. Therefore, one of the engineering challenges protein
designers face is paring down this complexity to focus on one or two functional roles for
their model system and progressively build up these functions, one amino acid at a time.
The design strategy for recreating structure and function in membrane-bound
synthetic proteins is achieved in three main steps: 1) extract the basic engineering
requirements from membrane oxidoreductases and reproduce them in hydrophilic (HP)
maquettes; 2) provide a structural basis for lipophilic (LP) maquette assembly into a
membrane; and 3) integrate properties from the HP and LP proteins designed in steps one
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and two into an amphiphilic (AP), transmembrane maquette. This work built upon from
established maquette families existing in the Dutton laboratory and published from other
sources to accomplish the third step – applying what has already been learned through HP
and LP designs towards reproducing transmembrane proton-coupled electron transfer
function into a simplistic AP maquette design, named AP6.
3.1.1 Step 1: reproducing membrane protein function in HP maquettes.
As outlined in chapter one, the main functional elements of biological energy
transduction are conversion of light or chemical redox energy into electron transfer,
coupling electron transfer to proton translocation, and coupling protonmotive forces with
conformational changes.

As the mechanism of Complex III contains all of these

functional elements, the first step of protein design was to re-establish the hydrophobic
di-heme b subunit from Complex III as a HP four-helix maquette [16, 21].
Through the binary patterning of polar and non-polar residues, Regan and
DeGrado were the first to demonstrate that soluble four α-helix bundles could be
assembled from simple heptad repeat peptides [22]. In their work, polar residues were
positioned on the protein surface, and non-polar residues were aligned in the core of the
protein, creating hydrophobic interactions that drove the assembly of the helices into a
four-helix bundle protein. This simple design proved to be easily manipulated, creating a
family of HP maquettes able to bind many different types of cofactors, including hemes
[1, 3, 5, 16, 21, 23, 24], quinones [25, 26], flavins [27], iron-sulfur clusters [28], redoxactive tyrosine and tryptophan radicals [15, 29, 30], carboyxlate-bridged dimetal clusters
[31, 32], chlorophylls [33], and chlorins [34, 35].
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However, creating a peptide sequence that facilitates cofactor ligation and
function is not enough to create a successful maquette protein; all successful maquette
designs also have singular structures. Though the first HP maquettes relied upon global
hydrophobic sequestering rather than specific residue-residue contacts, design of nativelike singular structures in maquettes has now been approached by many different
methods [14, 16, 36-38]. The Dutton laboratory has relied upon iterative design to attain
successful structural resolution for the HP maquette family.

This design process

progresses from the assembly of a generic protein helical bundle, to insertion of cofactor
ligating amino acids, and finally towards iteratively testing and redesigning to engineer
function and singular structure.
As shown in Figure 3.1, Dutton laboratory maquette design began with the design
of H10H24, which was derived from three and half repeats of the LLKKLLE heptad
sequence. A tryptophan residue was incorporated near the N-terminus of the protein on
the exterior surface to facilitate optical detection using UV-visible spectroscopy methods.
Cofactor binding in this protein was achieved through replacement of two leucine
residues (Leu 10 and Leu 24) in the interior of the protein with histidine residues, and Nterminal disulfide-forming loops (CGGG) were incorporated between sets of helices to
reduce the possibilities for overall protein assembly to just two conformations – syn (all
helices parallel) and anti (helices anti-parallel, or facing in opposite directions). Variants
of this protein, such as H10A24, were also successfully created and characterized, and
were found to have allosterically regulated conformational switches (from all-syn to allanti) upon redox change of the bound heme cofactors [12].
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H10H24

L31M

HP family

BT family

AP family

Figure 3.1: The Dutton laboratory maquette family tree [1-5]. Purple regions
of the protein cartoons depict the locations of hydrophobic residues, red
regions correspond to acidic residues, blue regions represent basic residues,
and yellow regions indicate the placement of amino acids with carboxyamide
functional groups.
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This mobility between conformations was eliminated in the apomaquette L31M,
which incorporated β-branched amino acids in the interior of the protein to solidify a
singular structure. L31M was characterized by NMR [4] and by x-ray crystallography
[37] and then redesigned as HP-1, a disulfide-bridged two-α-helix peptide with two
histidines for heme ligation [3]. This peptide retained the singular structure of L31, as it
self-assembled to form an anti four-helix bundle, and also maintained the strong coupling
between heme redox reactions and glutamate acid-base transitions initially designed in
H10H24.
With a basic heme-binding HP scaffold in place, the HP design evolved through a
series of iterative modifications to create HP7, an oxygen transport protein with
properties and function remarkably similar to neuroglobin [1]. Unlike its predecessors
H10H24 and HP1, HP7 only binds two hemes, with the histidine at residue 24 replaced
with a phenylalanine. Another structural difference that is the key to HP7 function is the
N-terminal loops are linked into a monomeric ‘candelabra’ structure, further constraining
water access to the heme binding site. Additionally, the rotation of three glutamate
residues into the protein core destabilizes one of the iron-histidine ligations, producing a
population of penta-coordinate heme that is then free to bind exogenous ligands such as
carbon monoxide or oxygen [1].
3.1.2 Step 2: Modifying HP designs to create proteins that can assemble in
detergent micelles or phospholipid bilayers.

As the HP proteins have been

progressively designed to shield water from their active site in order to stabilize the
formation of an oxy-ferrous state, some of the key design strategies employed by the HP
family of maquettes was applied towards the design of LP and AP maquettes. The same
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hydrogen bonding pattern in the HP protein core that forms its α-helical secondary
structure was also used in designs of membrane-associated peptides.
Once the secondary structure is formed, it must be inserted into a membrane
interface. Hydrogen bonding residues have sufficient thermodynamic driving force for
membrane helix association [39, 40]; however, the degree of stabilization in the
membrane is strongly dependent on the position of those residues within the membrane
interface. When asparagine is positioned in the middle of a membrane, it has been shown
to provide more stability than when it is located directly at the membrane-solvent
interface [41]. Additionally, certain sequence motifs have been demonstrated to aid
assembly of peptides in membranes. For example, Lear et al. demonstrated that the
incorporation of multiple serine residues in specific motifs drives the association of
simple transmembrane α-helices into higher oligomers that were then functional as ion
channels [42, 43]. Subsequently, Engelman et al. also confirmed that the incorporation
of multiple serine and threonine motifs drives transmembrane assembly [44].
The length of the peptide assembling into the membrane can also affect peptidelipid interactions [45]; however, hydrophobic mismatch between the membrane interface
and the peptide can be compensated for in peptide designs. Charged residues with long
and/or aromatic side chains (such as lysine or phenylalanine) can overcome hydrophobic
mismatch by partitioning into the headgroup region of the bilayer [46]. Additionally,
peptides with larger tilt angles can also accomplish membrane assembly with slightly
shorter lengths [45].
3.1.3 Step 3: Integrate properties from the HP and LP proteins into an AP
maquette. The design and construction of the AP family of maquettes was intended to
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Figure 3.2: Polar plot diagram for the AP6 peptide. There are three histidines in the
AP6 peptide sequence for heme ligation – histidine 10 (binding site “a”), histidine 21
(binding site “b”), and histidine 35 (binding site “c”). AP6 assembles as a four αhelix bundle in either lipid vesicles (top right) or detergent micelles (bottom right).

provide a simplistic platform for achieving functions typically carried out by more
complicated biological enzymes across a membrane interface. Three existing AP family
members were characterized previous to this work – AP1, AP2, and AP3 [2, 17]. AP1
combined 14 residues from HP1 with 24 residues from the membrane domain of the
natural M2 channel from the influenza virus through a flexible linking sequence
(GGNG).

This peptide assembled as a syn four helix bundle, and each assembled

maquette bound up to two heme cofactors via histidine ligation located in the HP domain.
Two variants of this maquette, AP2 and AP3, were created to explore heme-binding
characteristics in the LP domain. These maquettes removed the heme-ligating histidine
from the HP domain of AP1, and modeled their LP domain sequences after the
transmembrane helices found in the b-subunit of Complex III. These two variants were
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the first examples of successful cofactor binding sites within a designed peptide that were
located in a LP domain.
Selection of the primary sequence for AP6 was aided in part by what is known
about previously designed maquettes in the HP [1, 5, 12] and AP families [2, 17]. AP6
incorporates characteristics of many of its predecessors, as it has a HP-based domain
taken from HP7 and an LP-based domain built upon those tested in AP2 and AP3. AP6
has multiple heme binding sites (one within the HP domain and two within the LP
domain). This design, shown in cartoon form in Figure 3.2, was meant to combine the
best engineering elements learned from previous maquettes to become the first de novo
designed protein to establish transmembrane electrochemical and proton gradients akin to
those that occur in more complicated natural systems, such as Complex III.

3.2 Materials and Methods
3.2.1 Peptide synthesis and purification. Table 3.1 outlines the sequences of
AP6 and its mutants AP6a, AP6b, AP6c, AP6ab, AP6bc, and AP6ac. The peptides
described in Table 3.1 were synthesized on a continuous-flow solid-phase synthesizer
(CEM) using a standard Fmoc/tBu protection strategy on a Fmoc-PEG-PAL-PS resin
(NovaBioChem) on a 0.2 mmol scale. The peptides were purified on a reversed-phase
C18 HPLC column (Vydac) using a 65%-70% gradient of acetonitrile (Fisher) and water
both containing 0.1% (v/v) trifluoroacetic acid (Sigma). The purity and molecular weight
of the acetylated peptides were confirmed by matrix-assisted laser desorption/ionization
mass spectrometry (MALDI-MS), and the molecular weights of the mutant peptides are
listed in Table 3.1. Peptide yields were comparable to water-soluble peptides of similar
length [1].
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Table 3.1 Summary of the sequences and MW of AP6 and AP6 variants

Protein

MW (g/mol)

Sequence

AP6

5022

!"""#$%&'!"###()&&**(*!$"
*$)+*$$,($(,-!%&))*)*"#".

AP6a

5042

!"""#$%&'!"###()&&**(*'$"
*$)+*$$,($(,-'%&))*)*"#".

AP6b

5042

!"""#$%&''"###()&&**(*!$"
*$)+*$$,($(,-'%&))*)*"#".

AP6c

5042

!"""#$%&''"###()&&**(*'$"*
$)+*$$,($(,-!%&))*)*"#".

AP6ab

5032

!"""#$%&'!"###()&&**(*!$"
*$)+*$$,($(,-'%&))*)*"#".

AP6ac

5032

!"""#$%&'!"###()&&**(*'$"
*$)+*$$,($(,-!%&))*)*"#".

AP6bc

5032

!"""#$%&''"###()&&**(*!$"
*$)+*$$,($(,-!%&))*)*"#".

With the exception of pH dependent experiments, all experiments were performed
in buffered solutions containing 100 mM potassium chloride and 50 mM potassium
phosphate (pH 8.0). The word maquette refers to the desired total assembly of four
peptide helices. As such, our peptide concentrations reported here are for assembled
four-helix bundles. Peptide concentrations were determined by UV-visible absorbance
spectroscopy at 280 nm with an extinction coefficient of 22,400 M-1 cm-1 bundle-1
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calculated from the AP6 sequence using the Swiss Institute of Bioinformatics’ EXPASY
server (http://us.expasy.org/cgi-bin/protparam).
3.2.2 Peptide Solubilization. Water-insoluble AP6 peptides and their
assembled maquettes need a detergent for solubilization in aqueous buffers. We have
determined that, in general, common detergents near or above the critical micelle
concentration (CMC) readily solubilize AP6 maquette family members.

In these

experiments, dodecylphosphocholine (DPC) or Zwittergent was used to solubilize AP6
at a final concentration of 2 mM. AP6 can also be incorporated into phospholipids
vesicles.

Gregory Wiedman and Paul O’Brien pursued this line of solubilization.

Vesicles were prepared from a 9:1 mixture of 1-palmitoyl-2-oleoylphosphatidylcholine
(POPC) and 1-palmitoyl-2-oleoylphosphatidylserine (POPS).

The lipid mixture was

dried under nitrogen gas and then overnight under vacuum. The dry lipids were codissolved with a solution of AP6 in detergent, and then dialyzed against a buffer solution
without detergent.
3.2.3 Heme binding. A 1 mM stock solution of hemin (Sigma) was prepared in
20 mM potassium hydroxide and its concentration was verified using a standard
hemochrome difference spectrum, as described by Berry et al [47]. The aliquot of hemin
to be added was then determined based upon the concentration of the hemin stock and the
concentration of the AP6 solution. Then, the aliquot of hemin was added and stirred for
one minute, after which complete heme incorporation into AP6 was observed by a
spectral shift in the heme absorbance from unbound heme (380 nm) to bound, oxidized
heme (412 nm).

Aliquots were titrated in until the desired amount of heme was

incorporated into the protein.
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Solutions of millimolar zinc porphyrin were made in DMSO, and the exact
concentration of these solutions was also determined using a reduced – oxidized
absorbance differences and the extinction coefficient at 412 nm, 22,100 M-1cm-1. It was
important when measuring the concentration of the zinc porphryin solution that the stock
was not too concentrated, as the absorbance of millimolar solutions are difficult to
measure accurately. Therefore, though stock solutions for titrations were still millimolar
in concentration to limit the volume of porphryin added to the AP6 solution, this stock
was diluted by 10- or 100-fold in order to accurately determine the true concentration.
3.2.4 Analytical ultracentrifugation. A Beckman XLA/I analytical centrifuge
in the DeGrado laboratory was used to determine the molecular weight of self-assembled
AP6 complexes with and without hemin bound. The molecular weight of the complex
was assessed in a 5 mM DPC solution, and density was matched with D2O (51%) so that
the contribution of the detergent solution to the buoyant molecular weight of the peptide
complex would be negligible.

Sedimentation equilibrium experiments in density-

matched D2O solutions were done at 25 °C at four speeds (30,000, 35,000, 40,000, and
45,000 rpm) and two wavelengths (280 nm and 412 nm). Data analysis was completed
using the WatFitter4 program designed by Dr. James Lear in the DeGrado laboratory .
3.2.5 Circular dichroism (CD). Gregory Wiedman measured CD spectra of AP6
to determine its secondary structure. The CD trace shown was taken at 15 °C.
3.2.6 Oxygen binding determination. Stopped flow analysis of predominantly
mono-exponential binding kinetics of O2 and CO ligating with ferrous hemin in AP6
were followed spectroscopically in collaboration with J.L.Ross Anderson according to
published methods [1]. Rapid stopped-flow mixing of AP6 with CO gas concentrations
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from 2% to 50% saturation at 15 °C was completed using an Olis RSM 1000
spectrometer. Three different solubilization conditions for AP6 were used to determine if
the detergent/lipid composition had any effect on ligand binding: 2 mM DPC, 2 mM
Zwittergent,

and

incorporation

into

phospholipid

vesicles

comprised

of

2-

oleoylphosphatidylcholine (POPC) and 1-palmitoyl-2-oleoylphosphatidylserine (POPS).
The Olis machine scans both the α-band and Soret band absorptions 1,000 times per
second, which was then followed by SVD analysis of the kinetic components at each
wavelength.
3.2.7 Midpoint potential determination. Equilibrium redox potentiometry was
used as a functional analysis of the oxidation and reduction of hemes bound to AP6 [48].
Redox titrations were performed in an anaerobic 1 mL cuvette (Starna Cells) equipped
with a silver / silver chloride and platinum combination electrode (Microelectrodes Inc.).
All of the potentials reported are in reference to the normal hydrogen electrode (NHE).
The reduction potential of the cuvette solution was adjusted by adding 1 µL aliquots of
freshly prepared solutions of either sodium dithionite (for reducing) or potassium
ferricyanide (for oxidizing). 20 µL of a stock solution containing the following redox
mediator dyes was also added to the solution (final concentrations reported): 5 μM 1,2naphthoquinone, 5 μM 1,4- naphthoquinone, 20 μM duroquinone, 10 μM pyocyanine, 5
μM indigotrisulfonate, 10 μM 2-hydroxy-1,4-naphthoquinone, 1 μM indigocarmine, 10
μM anthraquinone-2-sulfonate, and 5 μM benzyl viologen. After equilibration at each
midpoint potential, the UV-visible spectrum of the AP6-heme complex was recorded,
monitoring in particular the increase in the sharp α-band absorption at 559 nm relative to
a 575 nm reference wavelength.
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3.3 Results
3.3.1 AP6 assembly. The molecular weight of the AP6 complex in DPC was
determined by analytical ultracentrifugation. The absorbance vs. radius data collected for
each sample was fit using the WatFitter4 program to determine the experimental
molecular weight for each sample. The aggregation number of AP6 was calculated by
dividing this experimental molecular weight by the molecular weight of a single AP6
peptide.

In experiments where hemes were added, the aggregation number was

determined by the following formula:
N = (MW – 652m) / 5022

Equation 3.1

where m is the number of hemes added per tetramer. The aggregation number for both
the apo and holo forms of AP6 was 4, indicating that AP6 assembles cleanly in micelles
as a tetramer. Experiments completed by Paul O’Brien and Gregory Wiedman also
confirmed tetrameric assembly of AP6 in lipid vesicles [8].
As shown in Figure 3.3, the weight fraction of over a range of concentrations
indicates that apo-AP6 assembles predominantly as a tetramer at millimolar
concentrations, but the population of AP6 is split between half monomer and half dimer
at micromolar concentrations of apo protein. Upon the addition of a heme, all other
species are eliminated, and AP6 assembles entirely as a tetramer. This suggests that
heme binding stabilizes the assembly of the four helix bundle.
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Figure 3.3: Analytical ultracentrifugation data for AP6 in its apo (left) and holo (right)
forms. Shown in top panels are the absorbances at 280 nm at different radii from the
center of the ultracentrifugation cell. Each trace represents a different speed: 40,000
rpm (red), 45,000 rpm (green), and 50,000 rpm (blue). This data was fit using the
WatFitter4 program to obtain the MW of the AP6 complex. The bottom panels depict
the weight fraction analysis of AP6 samples. AP6 assembles as a tetramer (blue trace)
at millimolar concentrations without heme, and its assembly is aided by adding heme
equivalents. With one heme equivalent bound, AP6 is solely a tetramer even at
nanomolar concentrations.
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Figure 3.4 A CD spectrum of 4 µM AP6 at 15 °C (data collected by Gregory
Wiedman). Secondary structure can be determined by CD spectroscopy in the far-UV
spectral region (190-250 nm), and AP6 displays spectral properties characteristic of a
helical structure. Helical content can be calculated using the molar ellipticity of AP6
at 222 nm, and from these calculations, AP6 is 92% helical.
Though analytical ultracentrifugation experiments verified the tetrameric
assembly of AP6, circular dichroism (CD) confirmed the secondary structure of the AP6
design to be comprised of stable alpha helices (Figure 3.4). The alpha-helical content of
a protein can be calculated by the following equation:
% a-helix = ([θ]222 nm-θC) / (θH - θC)

Equation 3.2

where θ222nm is the molar ellipticity at 222 nm, θH and θC are the baseline ellipticities for
the helix and random coil respectively. Using the empirical values of Rohl and Baldwin
[49]:
θH = 2220 – 53T
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Equation 3.3

θC=(-44000 + 250T)(1-3/Nr)

Equation 3.4

where T is temperature (in ºC) and Nr is the number of amino acid residues, tetrameric
AP6 is 92% helical at 15 ºC.
3.3.2 Heme binding in AP6. AP6 was designed to bind up to six bis-histidine
ligated porphryns. The binding site ligated to histidine 10 in the HP region is referred to
the “a” binding site, whereas the two sites located in the LP region at histidines 24 and 35
are named “b” and “c” respectively. Figure 3.5 shows a hemin titration of 2 µM AP6 in 2
mM DPC. The Soret absorbance of heme increases linearly with heme additions until
one heme per bundle is bound. This indicates that the first dissociation constant (Kd1) is
below the 5 nM resolution level of this experimental assay. The linear relationship
between the initial points can be used to estimate the extinction coefficient of the bound
heme, which reduces the number of unknowns in the Mathematica (Wolfram Research)
program used for fitting the heme titration data to heme dissociation constants. The AP6
binding data shown in Figure 3.5 were fit to six independent binding sites with
equilibrium binding constants of Kd1 < 5 nM, Kd2 = 70 nM, Kd3 = 1.4 µM Kd4 = 2.1 µM,
Kd5, Kd6 > 5 µM in 2 mM DPC. AP6 variants were fit to binding constants based upon
the number of available hisitidine binding sites. All of the Kd values for AP6 proteins are
listed in Table 3.2.
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Figure 3.5: Heme binding to a) 1.53 µM AP6 in 2 mM DPC b) 2 µM AP6 in DCM,
and c) 1 µM AP6 in POPC vesicles (completed by Gregory Wiedman). The curve in
a) can be fit to six different binding constants, representing all six binding sites found
in AP6. Those constants are: Kd1 < 5nM, Kd2 = 70 nM, Kd3 = 1.4 µM, Kd4 = 2.1µM, Kd5,
Kd6 > 5 µM.
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Table 3.2: Summary of Kd values for hemes bound to AP6 and AP6 variants
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Binding porphyrins that contain zinc is advantageous because these porphyrins
are then photoactivatable, allowing for the investigation of light-initiated electron- and
energy-transfer events between chromophores in multi-cofactor maquettes. Initial
ZnPPIX binding titrations were completed using AP6 solubilized in 2 mM DPC.
Previous maquette designs have demonstrated single-histidine axial ligation of ZnPPIX
[50], and fully assembled AP6 also adopts this coordination upon cofactor binding. As
shown by the initial linear dependence of bound heme absorbance to heme:bundle in
Figure 3.6, AP6 is able to bind up to seven ZnPPIX cofactors at nanomolar affinity
before the cofactor binding strength weakens.
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Figure 3.6 Titrations of a millimolar ZnPPX solution (in DMSO) added to 1 µM AP6
in 2 mM DPC (data obtained by Gregory Wiedman).
3.3.3 Redox potentials of hemes bound to AP6. Figure 3.7 illustrates redox
titrations of AP6 with varying equivalents of heme bound.

The titrations reveal a

splitting in redox potential that originates from a difference in heme environment due to

Figure 3.7 Redox titration of 4 µM AP6 in 2 mM DPC with two heme equivalents
added.
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Figure 3.8 Determination of the pKred and pKox for each of the AP6 heme b midpoint
potentials. Data was fit to Equation 3.7.

heme-heme charge interactions. The relationship between midpoint potential and pH was
explored for the hemes bound to AP6 and is shown in Figure 3.8. The higher potential
heme had a pKox of 6.1 and a pKred of 8.3. Over a modest pH range from pH 6.1 to pH
8.3, the slope was -57 mV/pH unit, indicative of a 1 e- / 1H+ relationship. The low
potential heme displayed a pKox of 7.2 and a pKred of 8.8. Interestingly, between those
pH ranges, this heme did not display the same 1 e- / 1H+ relationship shown for the higher
potential heme, but instead had a slope of -37 mV/pH unit.
3.3.4 Generation of the oxy-ferrous state in AP6. AP6 with reduced hemes
bound was tested to see if the hemes could ligate CO or O2. It was expected that since
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Figure 3.9: Forming the oxy-ferrous intermediate in 5 µM AP6 in 2 mM Zwittergent.
Panels a (Soret) and b (a-bands) depict the spectral changes associated with oxidized
(green), reduced (blue), and oxy-ferrous generation (red). Panels (c) and (d) reflect
the auto-oxidation rate of heme b from the oxy-ferrous state (Fe2+-O2) to the oxidized
form (Fe3+). These experiments were completed in collaboration with J.L. Ross
Anderson.
the HP domain of AP6 was based on the successful oxygen-binding HP7 protein [1], any
reduced hemes bound to this domain should also be able to ligate oxygen. Surprisingly,
AP6 only bound oxygen when solubilized in Zwittergent; DPC and phospholipid vesicles
were not successful environments for AP6-heme oxygen binding.
Figure 3.8 (a) and (b) depict the stopped-flow spectral changes for mixing
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reduced AP6 proteins with oxygen at 15 º C. The Soret (a) and α-band (b) spectra show
the transformation of the reduced heme b (blue) to the oxy-ferrous state (red), which
eventually becomes oxidized (green). Intermediate states are shown in gray. The autooxidation rates from an AP6 oxy-ferrous state (Fe2+-O2) to its oxidized state (Fe3+) were
measured with 1 (c) and 2 (d) hemes bound.
3.3.5 AP6 variants. Six variants of AP6 were created using solid phase peptide
synthesis to learn more about the individual characteristics of each heme binding site.
The heme binding properties of these mutants – AP6a, AP6b, AP6c, AP6ab, AP6ac, and
AP6bc – are listed in Table 3.2. The names of these mutants correspond with the binding
sites present as labeled in Figure 3.2; for example, AP6a retains the histidine at residue

Figure 3.10 Heme titration with 1.25 µM AP6ab. Though it has four binding sites
available, this AP6 variant very clearly binds only two tightly from the break in the
linear binding relationship that occurs after 2 hemes per bundle were added to the
solution. Kd values were determined to be Kd1 < 5 nM and Kd2 = 120 nM.
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10, but not at residues 24 and 35, where phenylalanine was substituted.
The variants were first analyzed by analytical ultracentrifugation to determine if
all of the heme binding sites were required for tetrameric assembly of AP6. AP6 does
not require all three heme binding sites to be present for tetrameric assembly. All of the
AP6 variant proteins containing single or multiple binding sites assembled as tetramers
except AP6c, which aggregated as an octomer in both its apo- and holo-forms.
The heme binding characteristics of the AP6 variants varied considerably from
the binding patterns associated with AP6, and are outlined in Table 3.2. Though the
mutants with a single heme binding site (AP6a and AP6b; AP6c was not tested since it
did not assemble as a four-helix bundle) both bound up to two hemes tightly, the mutants
that contained four heme binding sites (APab, APac, APbc) did not all bind up to four
hemes. AP6ab bound two hemes that were fit to binding constants around the nanomolar
constraint of the assay (Figure 4.10). AP6bc bound hemes weakly, with much of the
heme equivalents added remaining unbound.

3.4 Discussion
3.4.1 Design characteristics. The main principle of AP6 construction was the
same structured assembly driven by Regan and DeGrado [22] and its AP predecessors [2,
17] – a well-developed exterior pattern of polar and non-polar residues exposed along
the axis of the four-helix bundle.

However, it was important that these external

interactions did not conflict with the interior amino acids that make up the helix interface.
Additionally, a reasonably accurate prediction of the location of each residue was needed
to ensure that the metal porphyrin-ligating histidine residues within the interior were
properly aligned to ensure tight cofactor binding. The HP and LP domains each have
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their own amphiphilic exterior and interior patterns and specific interior residues that
need to be aligned with respect to one another in one helix. As shown in Figure 3.2, the
alignment of the two domains within the AP6 sequence was accomplished by plotting the
sequence on polar graphs that emphasize the angular position of each residue in the
sequence according to the following equation:
θ = 360° / r

Equation 3.6

where r is the number of residues per turn. Since the value of r cannot be determined
without structural characterization, polar plots were created using an r-value assumed
from the related protein structure of HP7 (3.58 residues per turn) and assuming an ideal,
straight a-helix with 3.6 residues per turn for the transmembrane portion, or a θ= 100°.
The sequence of the HP domain found in AP6 is 15 residues in length and
incorporates the bis-histidine ligating sequence from HP7 that was successful for tight
cofactor binding. The LP domain is based on the native hydrophobic heme binding
sequences from Complex III [6]. Complex III enzymes contain a conserved four-helix
bundle that ligates bL and bH between four histidine residues on helices b and d. As
shown in Figure 3.11, unlike the structure surrounding the bL site, where the diameter of
the four-helix bundle increases around the heme binding site to allow for interactions
with additional helical segments, the helical structure around the heme bH binding site
(residues 188-200) is a more ideal alpha helix. In the AP(2-3) designs, Complex III
residues 188-200 around the heme bH binding site served as a template for their LP
domain. The new AP6 design extends the sequence of the LP domain to 29 residues, but
does still maintain high homology with the sequence found in Complex III. In addition, a
four residue helix-capping sequence, GEGL, was used at the C-terminus to promote
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Figure 3.11 Crystal structures of native Complex III depicting its b subunit in blue
(left) and zoomed in (right). Shown in yellow are residues 188 – 200, where the
Complex III helix is the most ideal. The LP domain found in AP6 is based upon this
section of Complex III. This figure was drawn from PDB file 1BE3 [6] using Pymol
(DeLano Scientific and Schröedinger) software.
hydrogen bonding interactions that can be lost at the end of a peptide sequence. One
factor that simplified the AP6 design was that the tilt angle of the HP7 helix (5.1°)
closely matches the tilt angle calculated for Complex III (8.5°); therefore, the flexible
linking sequence found in the earlier AP1 design was not necessary in this design to link
the two domains. However, two phenylalanine residues were placed between the HP and
LP domains, because phenylalanine can successfully partition between polar and nonpolar interfaces due to its aromatic character.
3.4.2 AP6 may require additional structural constraints.

Though the

structure of AP6 is not yet known on a molecular scale, much is still known about AP6
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secondary structure and assembly. CD experiments reveal that AP6 is highly helical in
nature, and that its helical structure is stable over a wide range of temperatures and
denaturant concentrations [8]. High stability in the LP domain was expected for AP6 (as
was demonstrated by predecessor AP family members [2]) because disrupting hydrogen
bonds of alpha helices in a hydrophobic environment is energetically unfavorable. Not
surprisingly, the helical nature of the HP domain has been demonstrated in earlier HP
proteins [51], and is most likely further stabilized in AP6 by the LP domain.
AP6 assembles as a tetramer in its apo-form, and binding hemes stabilizes fourhelix bundle formation at higher concentrations. AP6 variants that lack one or more of
the three histidine binding residues are not able to maintain heme binding at all remaining
available sites in some cases. These results suggest that without all of the porphryn
coordinating histidines present in its sequence, AP6 may adopt different conformations
that do not promote heme binding, even though it is still assembled as a tetramer. Also,
removing the tightest binding site “a” in AP6bc may interrupt cooperative heme binding,
lowering the binding affinity for the “b” and “c” sites such that they no longer bind
hemes as tightly.
3.4.3 Heme properties in AP6. The observation of redox potential splitting
upon addition of just one heme cofactor demonstrates cooperative cofactor binding. In
this scenario, binding one heme in one binding site increases the affinity for the other
heme to bind in a binding site within the same maquette. When one heme is added, the
redox titrations are measuring the redox potential of a heterogeneous mixture of AP6
maquettes, where the half of the maquette population is comprised of apo-proteins and
half of the AP6 proteins have two heme equivalents bound.
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Therefore, the best

experimental conditions for redox titrations are to bind at least two hemes so that the
maquette population is homogenous.
The assembly topology of the maquette dictates the heme-heme distances, and
therefore heme-heme charge interactions, in maquettes with at least two hemes bound [2,
12]. AP6, like many previous maquette designs [1, 2, 5, 12, 17], assembles with a syn
topology (Figure 3.2). Maquettes with a syn topology, such as AP1 [2], H10A24 [5, 12],
or AP6, ligate two hemes in close proximity, leading to an electrostatic interaction
between the two cofactors. In AP6, a single midpoint potential value for that binding site
is split by ~75 mV when two hemes are added. This dramatic potential split is consistent
with an electric field effect – the heme with the -156 mV potential is titrated while
influenced by the electric field of an uncharged ferrous heme, while the heme with the 78 mV potential was titrated while in the presence of the electric field from the other
charged ferric heme.
The redox splitting information can be used to assign cofactor binding constants
to specific binding sites. In order for the hemes to have charge-charge interactions, the
hemes need to be in close proximity to one another. Therefore, the first two hemes
equivalents added need to either be bound to two identical binding sites (i.e. both hemes
bound at this bis-histidine 10 site) or in two sites directly adjacent to one another (i.e. one
heme bound at the histitine 10 site and one heme bound at the histidine 24 site). The
large splitting of ~75 mV in midpoint potential represents the same field strength and
charge-charge interaction energy observed in the H10A24 maquette [12], suggesting that
the interaction is derived from two hemes parallel to one another in identical binding sites
as they are in H10A24. As AP6a binds hemes more tightly than the other AP6 variants
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(Table 3.2), it is likely that the first two hemes in AP6 bind to the two binding sites at
histidine 10 before binding to the membrane-associated sites.
Successful formation of an AP6 oxy-ferrous state confirmed that construction and
assembly of AP6 maintains the symmetric rotation of key glutamate residues into the
maquette interior required in HP maquettes for oxygen binding, excluding water from the
redox active site. However, this occurs only in certain membrane interfaces. The heme
binding affinity must change when AP6 assembles in different membrane interfaces, as it
is the affinity of the heme that drives the rotation of the glutamates into the bundle
interior and weakens one of the histidine ligands enough to promote oxygen ligation [1].
Therefore, AP6 assembly varies when solubilized in different detergents (and lipid
compositions, though that was not explored in this thesis work).
3.4.4 Proton coupling to heme midpoint potential. Proton coupling to heme
oxidation and reduction requires that the pK value of an acidic or basic group on the
cofactor (or on a residue within the active site) shifts according to this thermodynamic
scheme:

Scheme 3.1
Oxidizing the cofactor increased its positive charge, decreasing the proton affinity (pKox)
of the acidic/basic group. Likewise, under reduced conditions, the proton affinity (pKred)
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is increased as the cofactor increases its negative charge. In regions between the pKox
and pKred, the midpoint potential of the cofactor will depend upon the protonation state of
the acidic/basic group, decreasing as the pH increases. For every proton coupled to one
electron from a cofactor, the slope of its pH dependence will be -59 mV.

These

conditions were evaluated for AP6 to determine the pKox and pKred for each of the hemes
bound.

The heme oxidation / reduction when coupled to protonatable residues is

described according to the following equation:

Equation 3.7
where E0 is the midpoint potential of the heme at low pH when all of the influencing
residues are protonated.
As shown in Figure 3.8, the high potential heme is dependent on a single proton
group, as its slope between its pKox and pKa red is -57 mV/pH unit, which is very close
to the ideal slope of -59 mV / pH for a 1 e- / 1 H+ process. The proton coupled to this
midpoint potential could either be associated with either of its bis-histidine ligands, or
glutamate residue 11, which is located within the heme binding site between the bundle’s
interior and exterior. There is some precedent for proton coupling with a glutamate
residue for hemes bound to AP maquettes; glutamate residues in AP1 were found to raise
the pKred above pH 8 in its ferrous state [2]. The lower potential heme displays a modest
proton dependence of -37 mV / pH unit between its pKox and pKred. This reflects more
than a full proton equivalent coupled to a single electron transfer, and could mean that the
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charge-charge interaction between the two hemes also affects its coupling to glutamate
proton exchange.

3.5 Conclusion
In this chapter, the maquette approach was applied to design a new member of the
AP maquette family, AP6. AP6 contains both a HP and a LP domain and assembles as
tetrameric α-helical bundles in detergents, organic solvents, or in lipid vesicles. Six
FePPIX binding sites are distributed within the AP6 sequence to create a transmembrane
cofactor chain, with two hemes binding in the HP domain (histidine 10), two hemes
binding at the solvent/membrane interface (histidine 21), and two hemes binding within
the LP domain (histidine 35).

The hydrophobic environment of the membrane increases

the redox potential of the bis-histidine bound hemes (in comparison to hemes bound to
the HP maquettes) and AP6 can withstand significant electrostatic interactions between
two bound heme cofactors.

Furthermore, AP6 has proton coupling to heme

oxidation/reduction over a modest pH range.
However common it might be for the Complexes within the mitochondrial
respiratory chain, complexity is not an essential requirement for enzymatic activity. This
simple AP6 design was created as a model system for studying the basic functions carried
out by the enzymes of the respiratory chain, such as Complex III: transmembrane
electron transfer, electron transfer with aqueous proteins, and proton-coupled electron
transfer. In chapter four, the extent of AP6 quinol-cytochrome c oxidoreductase activity
will be tested using standard Complex III steady-state activity assays.
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Chapter 4: Demonstrating quinol-cytochrome c
oxidoreductase kinetic activity by AP6

Given its sequence and heme binding capabilities, the AP6 design outlined in chapter
three could accomplish a variety of potential functions, including: transmembrane
electron transfer, electron transfer with aqueous proteins, and/or proton-coupled electron
transfer. In this chapter, AP6 is tested as a potential quinol-cytochrome c oxidoreductase
(Complex III) enzyme. As determined using standard Complex III activity assays, AP6
is the first example of a synthetic maquette with enzymatic activity within two orders of
magnitude of a natural protein. AP6 quinol-cytochrome c oxidoreductase activity can be
generated with a variety of reduced quinone substrates, and is dependent on the
concentration of cytochrome c present. With no obvious quinone-binding site included in
our protein design, AP6 provides clear evidence that an elaborate quinone-binding site
within a membrane protein is not essential for generating significant quinol-cytochrome c
oxidoreductase enzymatic activity from a heme protein. A version of the work in this
chapter is in preparation for submission to Biochemistry [1].
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4.1 Introduction
As outlined in chapters one and two, diffusible redox cofactors that link together
multiple protein complexes are critical to the design of Complex III. Catalytic sites for
oxidation and reduction of otherwise stable substrates, including quinone molecules
together with chains of redox cofactors, add speed and direction to electron transfer and
proton translocation to turn the free energy of oxidation-reduction reactions into a
transmembrane ΔµH+. These electron transfer reactions have been studied extensively;
however, an understanding of energy coupling as it relates to specific electron transfer
mechanisms within Complex III remains elusive. In order to address this problem, a
basic understanding of the structure, specificity, and functionality of membrane proteins
needs to be achieved. In chapter four, the maquette approach [2, 3] was applied to
engineer a simple transmembrane protein, AP6, to perform the same types of electron
transfer mechanisms found in more complicated protein systems. AP6 was engineered to
contain all of the benefits of a transmembrane cofactor chain capable of accelerating
electron and proton transfer without the structural or functional complexities that plague
our understanding of natural Complex III.
Complex III is a complicated redox enzyme with many aspects of its mechanism
undefined, but reproducing its quinol-oxidoreductase function should not be out of reach
for a transmembrane maquette protein.

Quinones are present in high cellular

concentrations (millimolar) and are also extremely mobile and reactive [4]. Even without
specific binding pockets for decylubiquinone explicitly designed, the hydrophobicity of
the quinone molecules coupled with excess concentrations in the cuvette works to
promote quinone association with the detergent micelle and hydrophobic AP6 maquette.
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Though no other protein has ever been specifically designed to mimic Complex III
activity specifically, AP6 is not the first example of a maquette protein designed for
catalysis. In 2004, Kaplan and DeGrado designed di-iron oxidoreductase mimics that
catalyzed the two-electron oxidation of 4-aminophenol (kcat / Km = 1500 M-1s-1) to the
corresponding quinone monoamine using a bound diiron cofactor [5]. The sequence of
this non-natural enzyme was designed using a computational method that considered
stabilizing known structural properties of previously designed dueferri (DF) family of
proteins, as well as destabilizing likely alternative protein folds. The catalytic efficiency
of this protein was sensitive to the size of the methyl group in the active site of the
protein, suggesting that the active site design was specifically engineered to maximize
catalysis.

Addtionally, de novo designed retro-adolase enzymes were created using

computational and directed evolution enzyme design strategies [6].

Recently,

Röthlisberger et al. applied those same techniques to create enzymes that catalyze the
Kemp elimination reaction, a model reaction for proton transfer from carbon, with
multiple turnovers on a seconds timescale [7]. Although the turnover rates for these
enzymes are lower than the rates of many natural proteins, all of these enzymes
successfully applied known structures towards the design of natural function and
signified the advancement of the protein design field. However, one plausible reason for
their lowered turnover rates could be that these proteins were designed to recreate a
singular structure of the active natural enzyme, ignoring any transition states that may be
required to fully reproduce the enzyme’s function. Therefore, one of the benefits of the
AP6 design is that its assembly and structure is controlled but not static, allowing for
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subtle structural movements that would be required for substrate interactions and
subsequent electron transfer reactions.

4.2 Materials and methods
4.2.1 Complex III growth and purification. Growth of the R. sphaeroides
strains was done as described in chapter two [8].

Chromatophore membranes and

purified Complex III were isolated and purified as described using a DEAE-sepharose
column (Amersham Pharmacia) [9, 10].
4.2.2. Peptide synthesis and purification. The peptide sequence of AP6 is:
CGGGEIWKQHEEALKKFFAFHFILPFIIMAIAMAHLLFLFGEGL.

AP6 peptides

were synthesized on a continuous-flow solid-phase synthesizer (CEM) using a standard
Fmoc/tBu protection strategy on a Fmoc-PEG-PAL-PS resin (NovaBioChem) at 0.2
mmol scale. The peptides were purified on a reversed-phase C18 HPLC column (Vydac)
using gradients of acetonitrile (Fisher) and water both containing 0.1% (v/v)
trifluoroacetic acid (Sigma). The purity and molecular weight of the acetylated AP6
peptide was confirmed by matrix-assisted laser desorption/ionization mass spectrometry
(MALDI-MS) to be 5022 g/mol. The peptides were purified without difficulty with
yields comparable to water-soluble peptides of similar length [2, 11].
Unless noted otherwise, all experiments were performed in buffered solutions
containing 100 mM potassium chloride and 50 mM potassium phosphate (pH 8.0). As
shown previously [12], the maquettes reported here assemble as tetramers; therefore, the
word maquette refers to the total assembly of four peptide helices. As such, our peptide
concentrations reported here are for assembled four-helix bundles. Peptide concentrations
were determined by UV-visible absorbance spectroscopy at 280 nm assuming an
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extinction coefficient of 22400 M-1 cm-1 bundle-1 calculated from the AP6 sequence using
the Swiss Institute of Bioinformatics’ EXPASY server (http://us.expasy.org/cgibin/protparam).
4.2.3 Peptide solubilization. Water-insoluble AP6 peptides and their assembled
maquettes need a detergent for solubilization in aqueous buffers. We have determined
that, in general, common detergents near or above the critical micelle concentration
(CMC) readily solubilize AP6 maquette family members [3, 12]. In these experiments,
we used dodecylphosphocholine (DPC) at a final concentration of 2 mM to solubilize
AP6.
4.2.4 Heme binding. A 1 mM stock solution of hemin (Sigma) was prepared in
20 mM potassium hydroxide and its concentration was verified using a standard
hemochrome difference spectrum, as described by Berry et al [13]. Though AP6 has
been shown previously to bind up to six hemes [12], in these experiments we chose to
bind four hemes, as the last two hemes were determined in chapter three to bind with
micromolar rather than nanomolar affinity. A 4:1 ratio of hemin to protein was added
and stirred for one minute, after which complete heme incorporation into AP6 was
observed by a spectral shift in the heme absorbance from unbound heme (380 nm) to
bound, oxidized heme (412 nm).
4.2.5 Reduction of decylubiquinone (DBH) substrate. Quinols were prepared
from the oxidized quinone using the method described by Peter Rich [14] and detailed in
chapter two. 0.25 g decylubiquinone was dissolved in 50 mL diethyl ether and placed in
a separatory funnel. A solution of 1 g sodium dithionite in 50 mL water was added and
the mixture was shaken together. The quinone could be seen to initially increase in
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yellow color due to semiquinone formation, but eventually became colorless as full
reduction to quinol occurred. The aqueous layer was removed, but the ethereal layer was
shaken with a second 50 mL solution of sodium dithionite to ensure completion of the
reduction reaction. After removal of the dithionite solution, the ethereal layer was washed
twice with a saturated sodium chloride solution. The ethereal layer containing quinol was
then passed through 30 g anhydrous sodium sulfate in a sintered glass funnel to remove
any residual water, and the ethereal solution was then dried down by rotovaporization at
25°C. The resulting white powder was dissolved in an acidic ethanol solution (95%
ethanol containing 10 mM hydrochloric acid) and flash frozen in 500 µL aliquots.
4.2.6 Enzyme steady state activity measurements. Maquette functionality as a
quinol-cytochrome c oxidoreductase was measured via its reduction of cytochrome c in
the presence of excess decylubiquinol [15]. A solution of 25 µM horse heart cytochrome
c (Sigma) in redox buffer (50 mM potassium phosphate and 100 mM potassium chloride
at pH 8) and 10 µM decylubiquinone (DBH) was incubated anaerobically in a 3 mL
cuvette and stirred for one minute, after which a maquette protein was introduced into the
cuvette in nanomolar concentrations (10-100 nM). Using an extinction coefficient of 18.5
mM-1cm-1 for the 551 nm – 540 nm difference absorption, cytochrome c reduction was
monitored over time until the amount of cytochrome c reduced reached a constant
maximum.
This cuvette assay was modified for anaerobic stopped flow experiments to obtain
the initial velocity for AP6 activity. An Olis multiwavelength stopped flow spectrometer
was used to measure cytochrome c reduction over 200 s.

100 µL from a syringe

containing 20 mM decylubiquinone in reaction buffer and DMSO was mixed with 100
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µL from a syringe containing 25 nM AP6 and 50 µM cytochrome c.
4.2.7 Computational work. As described in the Appendix, the Dutton
laboratory has developed an electron transfer rate expression that offers a simple way to
examine parameters that directly relate to the oxidoreductase activity of a particular
mitochondrial enzyme. The electron tunneling rates of the decylubiquinone, AP6, and
cytochrome c redox centers were simulated using Equation A.1 in user-written programs
constructed in Mathematica (Wolfram Research) to create a model for quinone
semiquinone stability and electron transfer distances [16, 17].

4.3 Results
The maquette approach enables the construction of useful synthetic proteins with
applications in the material science and medical fields. This approach has been so
successful because only the basic protein engineering requirements needed to obtain
enzymatic activity are applied to the designs, which have so far proven to be relatively
simple. To design AP6 to have quinol-cytochrome c oxidoreductase activity, the main
elements of these electron transfer reactions in Complex III were extracted and
incorporated into AP6: simple α-helical structure to promote membrane association, both
hydrophilic and hydrophobic sections of amino acids to promote interactions with both
the membrane and soluble molecules, multiple histidine sites for heme ligation, and a
tryptophan molecule for convenience when determining AP6 concentration.
4.3.1 Quinol-cytochrome c oxidoreductase activity of AP6.

We

demonstrated quinol-cytochrome c oxidoreductase activity in AP6 using a steady-state
turnover assay previously designed to determine Complex III activity (Figure 4.1) [15].
In this assay, a pool of reduced quinone reduces the hemes in the transmembrane protein,
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Figure 4.1: Cartoon representations of the components of the assay. Reduced
quinol molecules diffuse within reasonable electron transfer distances of both AP6
hemes and cytochrome c, though reactions with AP6 occur on a much faster
timescale than those with cytochrome c (background rate). The two electron
reduction of AP6 results in two, one electron reductions of cytochrome c
molecules.
transferring electrons across the membrane interface (Figure 4.1). The reduced protein
can then transfer electrons to the oxidized cytochrome c inside the soluble portion of the
detergent micelle. The transition from oxidized to reduced cytochrome c is monitored in
this assay, with activity traces reflecting the total amount of cytochrome c reduced over
time.
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Figure 4.2: Demonstration of quinol / cytochrome c oxidoreductase activity for AP6
in a standard Complex III activity assay, which monitors the reduction of cytochrome
c (as indicated by a difference in it 550-540 nm abosrabnce) over the time after AP6
is added. In the presence of 10 µM reduced DBH, 50 nM AP6 (green) reduces 25
µM cytochrome c in a 2 mM DPC detergent solution over two orders of magnitude
better than free hemin (red), or the background rate when apo-AP6 is present (blue).
The rate of AP6 reduction is approximately 100 fold slower than Complex III
(black).

As shown in Figure 4.2, decylubiquinone is significantly reactive with
cytochrome c even without the aid of a catalytic protein, such as Complex III. We left
the background rate in the initial time points visible in this figure so that any changes
induced by protein additions would be more evident; however, this rate was subtracted
from the data to determine the true rate of cytochrome c reduction caused by the addition
of AP6. The rate of cytochrome c reduction is unchanged when apo-AP6 is added;

88

Figure 4.3: Rates of cytochrome c reduction of 10 nM AP6 with varying ratios of
hemes bound per bundle as reported by stopped flow data with 25 µM cytochrome c
and 10 µM DBH present.

adding hemin alone only stimulates this background rate slightly. However, upon the
addition of AP6 with just two heme equivalents bound, cytochrome c reduction takes off,
occurring at a rate ~500-fold faster than the background rate and within 100-fold of the
rate of R. capsulatus Complex III. Though the design of AP6 supports up to six hemes
bound per maquette bundle, only two hemes are needed to achieve this maximal
enzymatic activity (Figure 4.3).
In complementary stopped-flow experiments, the cytochrome c substrate
concentration is varied to resolve kinetic parameters for the various proteins tested in this
assay (Table 4.1, Figure 4.4). As expected, AP6 activity increased with increasing
amounts of cytochrome c, reaching a maximal activity of 62 nM / s. The Km for
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Figure 4.4: Solutions containing 25 nM AP6 with 4 hemes bound and varying
cytochrome c concentrations were mixed with equal volumes of a solution containing
20 µM decylubiquinone. Data was fit to steady state kinetics of an enzyme with a
single substrate to determine initial velocities and kinetic parameters.
cytochrome c association with AP6 was 14.5 µM, which is almost identical to the Km for
cytochrome c with Complex III of 13.4 µM [18]. In contrast, the concentration of
decylubiquinone in these assays does not have any affect on AP6 activity once the
background rate is accounted for because quinone levels are already saturating in this
assay.
4.3.2 Testing AP6 activity with alternative quinone substrates Successful
reduction of AP6 by a quinone pool is not specific to an excess of ubiquinone present;
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Figure 4.5: Varying the quinone substrate: decylubiquinone (green),
decylplastiquinone is added (orange), and ubiquinone-2 (blue). Ubiquinone-50 in
organic solvents was inactive (red), but did show activity when solubilized in a solvent
and 2 mM DPC mixture (purple).
several other quinone molecules are able to successfully initiate AP6 turnover (Figure
4.5).

We have determined that, like cytochrome b6f found in chloroplasts and

cyanobacteria [19], decylplastoquinone yields AP6 turnover that is slightly faster than the
turnover reported for decylubiquinone.

In addition to varying the R-groups on the

quinone ring, the isoprene tail of the molecule can also be varied to some degree with
successful enhancement of the background rate. Ubiquinone-2 does reduce AP6, though
at a slower rate than the decylquinone molecules. However, it was more difficult to add
the extremely water-insoluble ubiquinone-50, which is the natural substrate for Complex
III in chromatophore membranes. Adding the UQ-50 with DPC detergent side steps some
of these solubility issues and leads to enhanced activity in the presence of AP6.
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Figure 4.6: The assay was completed under aerobic conditions to see if oxygen was
required for AP6 activity. Though the presence of oxygen does increase the number
of turnovers AP6 can complete (green), it does not change the turnover rate observed
in anaerobic conditions (red). However, adding superoxide dismutase prior (blue) or
after (purple) the addition of AP6 does not limit AP6 activity, suggesting superoxide
is not formed in this reaction in high enough quantities to have an effect on the
reaction rate.

4.3.3 Observing changes in AP6 activity in the presence of oxygen. The
experiments described above were performed anaerobically to minimize the role played
by oxygen. However, when AP6 activity assays were performed in the presence of
oxygen, the addition of SOD does not change the amount of cytochrome c reduced
(Figure 4.6); this indicates that reduction of cytochrome c by quinol via AP6 in the
presence of oxygen is not dominated by a superoxide-mediated mechanism.

92

Table 4.1 Summary of AP6 activity

Protein
Complex III

AP6

Em (mV)
FeS
bL

+280
- 200

heme1 -156
heme2 -78

kcat (s-1)

Km (+M)

kcat / Km

!"#"$
hemes
bound
%&'()

200

13.2

1.63 x 107

2

4.1

14.5

3.12 x 105

4

4.4 Discussion
As shown in Figure 4.2 and Table 4.1, AP6 clearly demonstrates significant
quinol-cytochrome c oxidoreductase turnover, being the first maquette protein to match
near-natural levels of activity. Here we outline a model for how AP6 functions so well
and suggest a role for our designs in understanding more complicated electron transfer
systems in the mitochondria.
4.4.1 Developing a model for AP6 heme reactivity.

There are several

possible combinations for heme binding in AP6 when four hemes are bound, and it is
certainly possible that our assays actually contain a mixture of AP6 proteins that have
different arrangements of heme binding. However, based on the heme affinity studies
completed in chapter four, we assume that the AP6 that is most populated in this assay
has two hemes bound in the heme binding site located in the water soluble extension of
the 4-helix bundle (histidine 10) and two hemes bound in the nearest membrane binding
site (histidine 24). Even without a heme in the third membrane binding site (histidine
35), the electron transfer distance between the second heme and cytochrome c would be
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approximately 8.5 Å, which is still allows for electron transfer reactions to occur on the
millisecond timescale we observe in these experiments.
Figure 4.3 illustrates that AP6 activity is halved when only one heme is bound.
Due to cooperative heme binding in AP6, when one heme equivalent is added, there are
two distinct populations of AP6 present – 50% apo-protein, and 50% of AP6 with two
hemes bound. Therefore, as the concentration of active AP6 is cut in half, it is not
surprising that AP6 can only reduce cytochrome c at half the rate. Additionally, apoproteins present will interact with cytochrome c substrate molecules, impacting the
amount of substrate available to active AP6.
It is known that oxygen can interact with reduced quinones to produce superoxide
intermediates that can in turn reduce cytochrome c.

Indeed, the presence of oxygen

leads to substantial background rates when quinone and cytochrome c (but not AP6) are
present. In order to eliminate oxygen from contributing to the background rate and/or the
measured enzymatic rate, the assays were conducted under anaerobic conditons.
Additionally, AP6 was exclusively solubilized in DPC, a detergent micelle system that
does not allow for the formation of an AP6 oxy-ferrous intermediate state. However, as
the natural Complex III can generate superoxide upon turnover (under certain redox
conditions), it was necessary to test whether or not AP6 quinol-cytochrome c turnover
also generated superoxide in the presence of oxygen, and if limiting superoxide
production in the aerobic assay caused a dramatic difference in AP6 turnover rate.
The turnover rate of AP6 was unaffected in the presence of oxygen, though the
total amount of cytochrome c reduced was increased (Figure 4.6). However, the addition
of SOD to the reaction cuvette did not limit AP6 activity or quench turnover. This
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suggests either that the levels of superoxide generated in this assay are not high enough to
activate SOD, or that the role of oxygen in this reaction is limited. It is also possible that
any superoxide formed in the presence of oxygen is rapidly converted to hydrogen
peroxide (and thus, not quenched in the presence of SOD); however, levels of hydrogen
peroxide cannot be tested under these assay conditons because cytochrome c is an
indirect redox partner for the horseradish peroxidase system commonly used to measure
hydrogen peroxide concentrations.
4.4.2 Thermodynamic constraints on AP6 activity. The initial transition from
quinol to semiquinone as an electron is transferred to AP6 is an uphill step, and is
thermodynamically unfavorable (Figure 4.7). However, a similar uphill step is expected
in native Complex III as a reduced quinol molecule at the Qo site transfers an electron to
oxidized FeS [20, 21]. We expect the uphill step in AP6 to be much larger than in native
Complex III, which may explain why the reaction is slower (Figure 4.7). Changing the
thermodynamics of this very important electron transfer step may prove to enhance AP6
turnover. Work ongoing in the laboratory involves modifying AP6 to bind hemes with
significantly higher midpoint potentials, such as heme a. In the meantime, altering the
thermodynamics of this reaction was explored with HP7, which has already been
engineered to accommodate a variety of heme cofactors, as detailed in chapter five.
4.4.3 AP6 activity is not decylubiquinone specific. It is not surprising that
AP6 is able to receive electrons from a variety of quinone substrates, as a specific
quinone binding pocket within the protein was not engineered.

Also, though most

Complex III proteins use pools of ubiquinone as substrates for the Qo and the Qi site,
their activity is not dependent on ubiquinone specifically – Complex III activity is

95

Figure 4.7: The thermodynamics of Complex III and AP6 electron transfer are
structured in a similar way. Both Complex III (top) and AP6 (bottom) have
reactions that are unfavorably uphill followed by favorable (downhill) reactions.
In Complex III, the uphill step is the initial electron transfer reaction between the
QH2/SQ at the Qo site and the FeS cluster, and in AP6, the QH2/SQ to heme b
electron transfer step is unfavorable. Quinol reduction of AP6 is four times more
unfavorable than the uphill step in Complex III, and could account for the
difference in AP6 and Complex III activity.
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maintained when alternative quinones are substituted into the Qo site [22]. Particularly
since plastoquinone is used naturally by cytochrome b6 f, a Complex III analog, it was
expected that plastoquinone and ubiquinone would work equally well as electron donors
in this assay.
Depending on the substituents or the length of the isoprene tail, different quinones
will interact with AP6 differently. Based on the quinones tried in this work, the isoprene
tail seems to dictate AP6 activity levels, presumably due to their regulation of quinolAP6 proximity. Hydrophobic quinones such as decylplastoquinone and decylubiquinone
will associate with the detergent micelle better because they have more isoprene groups,
bringing the quinol closer to the b hemes bound to AP6. Not surprisingly, AP6 turnover
is the essentially the same in the presence of either of these substrates.

Though

ubiquinone-2 is also capable of acting as an electron donor to AP6, it likely does not
associate with the detergent as well due to a much shorter hydrophobic tail, limiting its
electron transfer with AP6.
4.4.4 Estimating semiquinone stability of the “Q-pool” and Q-heme b
electron transfer distances. The rate of electron transfer through AP6 is likely to be
dependent on the individual one-electron redox couples of the two-electron quinone
substrate—that is, on the stability constant of the quinone substrate. When the midpoint
potential of the first electron added to fully oxidized quinone is more negative than the
midpoint potential of the second electron, then the intermediate semiquinone is unstable
and the stability constant is less than 1. Electron tunneling rate calculations give us some
idea of what the tunneling distance and stability constants might be. Here we work with
quinones that all have very similar semiquinone stability, but we can model the effect

97

Figure 4.8: The Moser-Dutton equation for calculating electron transfer rates was
used to model ranges of semiquinone stability and electron transfer distances that
would produce AP6 turnover on a given timescale. Shown on the y-axis are values for
the semiquinone stability constant on a logarithmic scale, and depicted on the x-axis
are values for the electron transfer distance between the AP6 hemes and cytochrome c.
Each line depicts a timescale (logarithmic scale), with the lines in bold indicating
nanoseconds (-9 in box), microseconds (-6), milliseconds (-3), and seconds (0) and
dashed lines indicating ranges in between these values. As the kcat of AP6 indicates
each turnover occurs on a millisecond timescale, we were particularly interested in the
values falling within the light green range of the graph.

varying semiquinone stability would have when the midpoint potentials of the hemes in
AP6 are fixed using the Moser-Dutton equation (Figure 4.8). In order to achieve the
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reaction on a millisecond timescale, the semiquinone stability constant of the Q-pool
would need to be between 10-9 to 10-20, indicative of an unstable semiquinone
intermediate.

Therefore, it is most likely that the quinone here does not form an

appreciable semiquinone intermediate at all, but transfers two electrons concertedly to
two of the hemes bound to AP6. This also agrees with our observation that only two
hemes are required to achieve maximal activity (Figure 4.3).
As no structural data exists for the substrate-AP6 complexes in this assay, the
exact electron transfer distances between the cofactors are unknown and could also affect
enzyme turnover. We can use the heme binding information known about AP6 along
with docking studies of cytochrome c and Complex III [23] to assume the electron
transfer distance between the b-hemes bound to AP6 and the c-heme in cytochrome c to
be approximately 8.5 Å. This assumption allows us to model possible distances between
the reduced quinol molecules and the AP6 hemes, which is more of an unknown because
there is not a fixed binding site for quinol within AP6. As indicated by Figure 4.8, to
achieve a reaction on a millisecond timescale (green section of graph), the distance
between the quinol and heme b is limited to a range of 3.5 – 7.5 Å if the semiquinone is
unstable. Short electron transfer distances between the heme and quinol could reasonably
occur; the hydrophobicity of the quinone molecule allows it to partially associate with the
DPC detergent micelle, shortening the distance the electron has to travel between the
quinone and AP6’s heme cofactors. Additionally, it is possible that the quinone pool in
this experiment is associating with AP6 non-specifically, as this behavior has been
observed for other synthetic proteins [24]. This would enable the quinone to partition
into the hydrophobic core of the protein, promoting a stronger interaction with hemes
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bound to AP6 at very short distances. Quinone/heme electron transfer appears quite
possible using the simple enzymatic principle of proximity--securing quinone at a
specific binding site or manipulating the quinone stability constant through specific
interactions with the protein do not appear essential for catalysis.

This simple proximity

model for quinone reactivity with heme proteins is not an unrealistic representation of
how these electron transfer processes occur in biological membranes; it is wellestablished that the ubiquinone at the Qo site is highly mobile, initiating Complex III
turnover when it is bound. As no evidence for specific quinone-protein interactions have
been established at Qo, it is reasonable to assume that our experiments demonstrate a
very important piece of biological engineering – quinone concentrations need only to be
in excess at a particular active site in order to generate substantial turnover.
This model could be tested through the development of an AP6 protein that
contains a quinone amino acid fixed in position within the soluble region of the maquette.
Previous experiments incorporating a napthoquinone amino acid, Naq, into a small
peptide have demonstrated that Naq is spacially equivalent to a tryptophan residue [25].
Therefore, Naq can be readily added to the AP6 peptide sequence without large
disruptions in protein assembly or heme binding. Fixing the quinone into one position in
the maquette would answer definitively whether or not quinone-protein interactions are
essential for maximal enzymatic turnover.

4.5 Conclusion
This work was able to translate a complicated mitochondrial redox enzyme into a
simple, transmembrane electron transfer chain that still retained all of the necessary
engineering elements to accomplish quinol-cytochrome c oxidoreductase activity within
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Figure 4.9 Comparing AP6 (green arrow) kcat to other de novo designed enzymes (red
arrows) [5-7], and natural turnover rates (black arrows).

two orders of magnitude of the natural rate. The hemes bound to AP6 were able to
receive electrons from quinone substrates and reduce cytochrome c on a millisecond
timescale. Figure 4.9 compares AP6 activity to the turnover rates for previous de novo
designed enzymes [5-7], the background rate for quinol to cytochrome c electron transfer,
and Complex III steady-state turnover rates. AP6 improves upon the catalytic rates of
other designed oxidoreductases, and begins to bridge the gap between the rate of
uncatalyzed cytochrome c reduction and the rate of Complex III turnover.
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Chapter 5: Testing the thermodynamic limits of
maquette quinol-cytochrome c oxidoreductase
activity

As shown in chapter four, the electron transfer between a quinol molecule and the AP6
maquette is a drastic uphill reaction, and limits the rate at which AP6 can turnover.
However, if the midpoint potential in the maquette were raised, the thermodynamic
barrier for quinol to heme electron transfer would be lowered. In this chapter, the effect
of modulating maquette midpoint potential on the rate of cytochrome c reduction is
determined. For these studies, a library of soluble maquettes was chosen, primarily
because they are able to bind a variety of heme-based cofactors in addition to heme b,
yielding a wider range of midpoint potentials to test. From measuring the activity of
proteins that have a range of different midpoint potentials, the thermodynamic limit for
quinol-cytochrome c activity by a soluble maquette was determined for this assay. HP7
maquettes that contain hemes with measured midpoint potentials lower than -150 mV are
inactive, indicating that the quinol/semiquinone to heme electron transfer step has
reached an insurmountable thermodynamic barrier.
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Figure 5.1: Structures of heme-based cofactors available to bind to HP7. Heme b (in
the form of protoporphyrin IX) is shown in red, heme a and diacetyldeuterioporphyrin
IX (a heme a mimic) in green, and iron(III)-dicyanodeuteroporphryin in teal.
	
  

5.1 Introduction
Chapter four revealed AP6 to be the first synthetic enzyme to achieve near-natural
levels of Complex III enzymatic activity.

However, one potential limitation on its

turnover rate is the uphill electron transfer step between quinol and AP6.

In order for

this electron transfer reaction to become more favorable, the midpoint potential of hemes
bound to AP6 needs to be raised. One convenient way to lower the thermodynamic
barrier for quinol to maquette-cofactor electron transfer is to substitute the FePPIX
cofactor bound with hemes that have higher midpoint potentials. However, though AP6
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Figure 5.2: Absorbance spectra for HP7 with 1 cofactor equivalent bound. Shown in
green is HP7 with heme a bound, in red HP7 with heme b, in blue HP7 with iron-2,4diacetyldeuterioporphyrin IX (data courtesy of Ross Anderson) and in teal HP7 with
iron(III)-dicyanodeuteroporphryin.
	
  

	
  

can successfully bind Fe- and ZnPPIX [1], its binding sites have not demonstrated tight
binding with other porphyrin-based cofactors.
Soluble maquettes have been modified to bind a variety of different heme
cofactors [2-8]. HP7 was chosen for this study because it is extremely well characterized
[6] and shares sequence identity with the HP domain found in AP6. Shown in Figure 5.1
are the structures of four cofactors that can bind tightly to HP7 – heme b, heme a,
iron(III)-dicyanodeuteroporphyrin (dicyano), and iron-2,4-diacetyldeuterioporphyrin IX
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(DADPPIX) – and Figure 5.2 depicts characteristic absorbance spectra for each of the
HP7-heme complexes. In heme a, the FePPIX C-8 methyl group is oxidized into a formyl
group, and the vinyl group on C-2 is converted into a hydroxyethylfarnesyl side chain.
DADPPIX is a heme a analog that substitutes the two vinyl groups found in FePPIX for
acetyl groups. The dicyano heme is very similar in structure to DADPPIX, with the acetyl
groups replaced by nitrile groups. A c-type HP7 protein also exists; however, heme c
was not chosen for this work because its absorbance profile overlaps with that of the
natural cytochrome c monitored in the assay (Figure 5.2).
Electron withdrawing groups present in heme a and DADPPIX have been shown
to be responsible for raising the midpoint potential
comparison to when heme b is bound.

of maquettes upon binding, in

For example, the presence of the electron

withdrawing formyl group in heme a has been shown to raise the midpoint potential of
soluble maquettes by destabilization of the ferric state [2, 4]. The midpoint potential of
FePPIX in HP7 [6] (Table 5.1) is considerably lower than has been observed for its
soluble maquette predecessors [4, 9], and it was expected that the midpoint potential of
HP7 would be substantially increased by the introduction of electron withdrawing
substituents on the heme because HP7 has a net charge of -14. The range of midpoint
potentials available within the HP7 design allows for the direct control of quinol to heme
electron transfer thermodynamics, yielding an opportunity to directly test whether
manipulating maquette midpoint potential is enough to dictate its enzymatic function.

5.2 Materials and methods
5.2.1 Maquette preparation. All soluble maquette proteins were designed and
synthesized by other members of the laboratory, and concentrated stocks of each protein
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were donated for the completion of this work. Stocks of HP7 were obtained from Ross
Anderson and BT3 was obtained from Tammer Farid and Bruce Lichtenstein.

All

concentrated stocks were diluted to their final concentrations with a 250 mM pH 9 borate
buffer containing 100 mM potassium chloride, as both of the soluble maquettes required
alkaline pH conditions to bind heme cofactors.
5.2.2. Heme stock preparation. A 1 mM stock solution of hemin (Sigma) was
prepared in 20 mM potassium hydroxide and its concentration was verified using a
standard hemochrome difference spectrum, as described by Berry et al [10].

Stocks of

dicyano in DMSO were obtained from syntheses completed by Bruce Lichtenstein [11].
Stocks of heme a in DMSO were obtained from Ross Anderson.
5.2.3 Heme binding. Each of the soluble maquettes has the capacity to bind up
to two heme cofactors. Based on the concentration of the protein stock, the concentration
of the heme stock needed to add 0.1 aliquot was determined. Hemes were titrated into
the maquettes in 0.1 aliquots until the desired number of equivalents was added into the
solution. Then, the maquettes were passed down a PD-10 desalting column to separate
unbound heme from the maquette-heme complex. This procedure was modified from a
protocol published previously [6]. Samples of HP7 with DADPPIX bound were obtained
from a frozen stock made by Ross Anderson, and did not require this step.
5.2.4 Midpoint potential determination. Equilibrium redox potentiometry was
used as a functional analysis of the oxidation and reduction of hemes bound to HP7.
Redox titrations were performed in a similar fashion to those completed in previous
chapters using an anaerobic 1 mL cuvette (Starna Cells) equipped with a combination
electrode (Microelectrodes Inc.). All of the potentials reported are in reference to the
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normal hydrogen electrode (NHE). The reduction potential of the cuvette solution was
adjusted by adding microliter aliquots of freshly prepared solutions of either sodium
dithionite (for reducing) or potassium ferricyanide (for oxidizing). 20 µL of a stock
solution containing the following redox mediator dyes was also added to the solution
(final concentrations reported): 5 μM 1,2-naphthoquinone, 5 μM 1,4- naphthoquinone, 20
μM duroquinone, 10 μM pyocyanine, 5 μM indigotrisulfonate, 10 μM 2-hydroxy-1,4naphthoquinone, 1 μM indigocarmine, 10 μM anthraquinone-2-sulfonate, and 5 μM
benzyl viologen. After equilibration at each midpoint potential, the UV-visible spectrum
of the maquette was recorded, monitoring in particular the increase in the sharp a-band
absorption for each heme relative to a reference wavelength. The data were analyzed
using the Nernst equation, fitting to an n=1 electron transfer process.
5.2.5 Enzyme steady state activity measurements. As described in chapter
five, maquette functionality as a quinol-cytochrome c oxidoreductase was measured via
its reduction of cytochrome c in the presence of excess decylubiquinol [12]. A solution of
25 µM horse heart cytochrome c (Sigma) in redox buffer (50 mM potassium phosphate
and 100 mM potassium chloride at pH 8) and 10 µM decylubiquinone was incubated
anaerobically in a 3 mL cuvette and stirred for one minute, after which a maquette protein
was introduced into the cuvette in nanomolar concentrations (100 nM). Using an
extinction coefficient of 18.5 mM-1cm-1 for the 551 nm – 540 nm difference absorption,
cytochrome c reduction was monitored over time until the amount of cytochrome c
reduced reached a constant maximum.
	
  

For HP7 maquette complexes that demonstrated activity, this cuvette assay

was modified for anaerobic stopped flow experiments. An Olis multiwavelength stopped
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flow spectrometer was used to measure cytochrome c reduction over 200 s. 100 mL from
a syringe containing 20 mM decylubiquinone in reaction buffer and DMSO was mixed
with 100 mL from a syringe containing 200 nM HP7 and 50 µM cytochrome c.

Table 5.1 Midpoint potentials and kcat values at pH 8

Protein

Em8 (mV)

HP7 FePPIX
HP7 heme a
HP7
dicyanoheme
HP7 DADPPIX
dicyano heme
AP6

-280
-72
+62
-147
n.d.
-150, -75

Em8 reference
Ron Koder [6]
This work
This work
Ross Anderson [13]
n.d.
This work

kcat (s-1)
0.0062
0.54
0.63
0.21
1.2
4.1

5.3 Results
5.3.1 Determining the
midpoint

potentials

of

alternative hemes bound to
HP7. The midpoint potentials
of hemes bound HP7 are
reported in Table 5.1.
acetyl

groups

found

The
in
	
  

DADPPIX were found to raise
the midpoint potential of HP7
by 133 mV through weakening

	
  

Figure 5.3: Redox titration of 5 µM HP7 with 1
equivalent of heme a. Data was fit using the Nernst
equation with Igor Pro (Wavemetrics Inc.) software. 	
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the affinity of the bis-histidine
site for the heme iron [13], as
has been observed for other
soluble maquettes [14].

As

shown by the redox titrations in
Figures 5.3 and 5.4, heme a
	
  
Figure 5.4: Redox titration of 5 µM HP7 with 1
equivalent of iron(III)-dicyanodeuteroporphryin.
Data was fit using the Nernst equation with Igor Pro
(Wavemetrics Inc.) software. 	
  

	
  

and dicyano also raised HP7
midpoint
substantially.

potential
The midpoint

potential of bound heme a at
pH 8 is -72 mV, or 200 mV more positive than the potential measured for heme b. The
midpoint potential of the dicyano heme in HP7 was 62 mV at pH 8, an astounding 342
mV higher than heme b in HP7. This translates to a lower free energy for quinol to heme
electron transfer up to 33 kJ when heme b is substituted with alternative heme cofactors
in HP7.
5.3.2 Comparing AP6 activity to soluble maquette proteins. HP7 quinolcytochrome c oxidoreductase activity was determined using the steady-state turnover
assay discussed in chapter four (Figure 5.5) [12]. Shown in purple is the background rate
of cytochrome c reduction by DBH. The addition of the HP7-heme b maquette did not
enhance this rate (yellow trace), but HP7 demonstrated increasing levels of catalysis as
its midpoint potential was raised.

HP7-DADPPIX activity (red) was an order of

magnitude faster than the background rate and HP7-heme a (green) was twenty times
faster. A heme b control trace is shown in Figure 4.2; neither DADPPIX nor heme a in
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Figure 5.5 Quinol-cytochrome c oxidoreductase activity is shown for several
different maquette proteins. Activity was quantified as the absorbance difference
between reduced (550 nm) and oxidized (540 nm) cytochrome c over time. All
experiments were completed using buffered solutions containing 100 mM
potassium chloride and 50 mM potassium phosphate (pH 8.0). 25 µM cytochrome
c was incubated in a cuvette to establish a baseline absorbance, and then a
concentrated solution of DBH was added to establish a final concentration of 10
µM in the cuvette. After the background rate of direct quinol to cytochrome c
electron transfer was established (purple), the maquette proteins were added to the
cuvette. The soluble maquettes were added at a final concentration of 100 nM.
HP7 (yellow) with heme b did not have activity that was significant when
compared to the background rate. However, when cofactors such as DADPIV
(red) and heme a (green) were incorporated into HP7, HP7 activity increaed
significantly. Experiments with 25 nM AP6 (blue) were conducted slightly
differently than those with the soluble maquettes, as AP6 required the assay buffer
to also contain 2 mM DPC. AP6 activity was greater than even the most
catalytically-active form of HP7, 100 nM HP7 with heme a bound.
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Figure 5.6 Quinol-cytochrome c oxidoreductase activity is shown for HP7 and
AP6 with iron(III)-dicyanodeuteroporphryin (dicyanoheme) bound. Activity
was quantified as the absorbance difference between reduced (550 nm) and
oxidized (540 nm) cytochrome c over time. All experiments were completed
using buffered solutions containing 100 mM potassium chloride and 50 mM
potassium phosphate (pH 8.0). 25 µM cytochrome c was incubated in a cuvette
to establish a baseline absorbance, and then a concentrated solution of DBH was
added to establish a final concentration of 10 µM in the cuvette. After the
background rate of direct quinol to cytochrome c electron transfer was
established (purple), the maquette proteins were added to the cuvette. Though
100 nM HP7 (green) had considerable activity with 1 equivalent of the
dicyanoheme bound, adding 100 nM dicyanoheme (red) as a control
demonstrated more activity than when it is bound to the maquette.
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the absence of HP7 generated activity above the DBH background rate (data not shown).
Complementary stopped-flow experiments were completed to resolve the kcat values for
the various proteins tested in this assay (Table 5.1). When alternative hemes were bound,
HP7 had kcat values that were approximately an order of magnitude slower than AP6.
As shown in Figure 5.6, the HP7-dicyano maquette was more reactive than any of
the other HP7 complexes; however, the dicyano heme control experiment revealed that
the activity of the dicyano heme is greater in solution than bound to the protein, and is
almost equivalent to the quinol-cytochrome c oxidoreductase activity shown for AP6.
This was a surprising result, as none of the other hemes reacted as well in solution as they
did when incorporated into a maquette.

5.4 Discussion
5.4.1 Approaching and exceeding the thermodynamic limit for quinol to
heme electron transfer. HP7 is able to maintain turnover over a remarkably wide
range of for quinol to heme energy differences. As the barrier for quinol to heme
electron transfer is raised successively, HP7 activity decreases.

However, the

quinol/semiquinone to heme electron transfer step reaches an insurmountable
thermodynamic barrier when heme b is bound to HP7 and HP7 midpoint potential drops
to -280 mV.

Under these conditions, HP7 no longer contributes to cytochrome c

reduction, and only the DBH background reduction of cytochrome c is observed.
Midpoint potential differences between the different cofactors bound to HP7 can
explain most of the results in this chapter. One unexpected finding was free dicyano
heme displaying higher catalytic behavior in solution relative to when it was bound to
HP7. This can be explained in part due to the impact dicyano heme binding has on HP7
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mobility. Bruce Lichtenstein demonstrated that the HP7 histidines are tightly bound to
the reduced dicyano heme, eliminating HP7 helical rotations and oxyferrous generation
[11]. This indicates that this heme is buried within the core of the HP7 four-helix bundle
when it is bound, and much less accessible to diffusible substrates than it is in solution.
5.4.2 Impact of thermodynamic threshold on future AP6 designs. Though
this study revealed that lowering the thermodynamic barrier for quinol to heme electron
transfer significantly improved HP7 turnover rate, it also validated the design of
transmembrane maquette proteins. AP6 was still a better enzyme than HP7 even when its
reduction reaction was more unfavorable, suggesting that the midpoint potential of the
heme is not the most important factor for reproducing Complex III activity in a synthetic
enzyme. Instead, AP6’s strong interactions with its quinol and cytochrome c redox
partners is likely what makes it turnover at a near-natural rate.

The hydrophobic

environment provided by AP6 and/or its membrane interface helps the quinone substrate
bind closer to the AP6 hemes than it can in solution. Additionally, AP6 has the same
binding affinity for cytochrome c that natural Complex III does for cytochrome c2, which
is not reproduced in HP7.
Still, lowering the thermodynamic barrier for AP6 turnover could increase its
enzymatic activity, as was demonstrated for HP7. Subtle residue mutations around the
heme binding sites could change the electrostatic environment of the heme and may be
enough to shift AP6 midpoint potential. Shifman et al. determined that the elimination of
glutamate residues around the heme binding site of H10A24 raised the midpoint potential
of the hemes bound by 50 mV [4]. There are two glutamate residues, residues 11 and 12,
near the “a” binding site in AP6 that could be mutated to a neutral (but polar) residue like
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glutamine to raise AP6 midpoint potential. However, charge modifications have a higher
propensity for unexpected results and could require several iterative designs to see any
changes to the redox environment. Shifman et al. also observed that some mutations had
no effect because the rotation of the assembled helices was altered depending on the
charges on the helix, driving mutated residues away from the hydrophobic core and
reducing their effect [4].
In the meantime, AP6 could be redesigned to be more accommodating to
alternative heme cofactors that would raise its midpoint potential. AP6 may be limited in
the cofactors it can bind tightly because it currently does not have any designed-in control
over its structural assembly. Structural constraints could be implemented into the AP6
design to limit conformational flexibility and promote alternative heme binding. A loop
sequence (GGSGCGSG) would link two sets of two AP6 helices through a disulfide
bond, yielding the single “candelabra” structure adopted by HP7. This new design would
require the development of an AP6 expression system, as the length of two AP6 helices
linked by the loop sequence would far exceed what is recommended for solid-phase
peptide synthesis.

5.5 Conclusion
This work clearly demonstrated that quinol to heme electron transfer is the ratelimiting step for maquette turnover. Raising the midpoint potential of the HP7 model
system, and therefore lowering the thermodynamic barrier for quinol to heme electron
transfer, increased both HP7 catalytic rate and the total amount of cytochrome c substrate
reduced.
	
  
	
  

This work also revealed that transmembrane maquettes are able to perform
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electron transfer functions that are inaccessible to soluble protein designs. When HP7
activity was maximized, it still reduced cytochrome c an order of magnitude slower than
the AP6 design. This suggests that having a favorably redox-active maquette is not the
minimum requirement for generating successful model systems to study mitochondrial
respiratory chain electron transfer processes. The main functional elements involved in
biological energy transduction are invariably contained within membranes and directed
vectorially across these membranes.	
  Therefore, creating a library of maquettes capable of
reproducing key steps in energy transduction depends upon the redesign and expansion of
the AP maquette family.
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Chapter 6: Conclusions

Complexity is not an essential requirement for transmembrane proton and electron
transfer. The work in this thesis has generated a list of important engineering elements
that dictate Complex III activity and supports a simple model for Complex III turnover
where electron tunneling reactions are rate-limiting. In this chapter, I will discuss the
implications this kind of model will have on the field of Bioenergetics and suggest future
directions that could be explored to define a mechanism for Qo oxidation. Portions of
this chapter have been included in the following references and are reprinted with
permission from SpringerLink and the Journal of Bioenergetics and Biomembranes [1,
2].
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6.1 Complex III assembly instructions
While there is still progress to be made in the field of de novo design, artificial
proteins display redox functional characteristics that are within reach of the engineering
of natural enzymes [3-5]. The main goal of the maquette approach is to uncover the
assembly instructions required to put together biological functions by asking basic
questions about how proteins work: How many engineering elements are required?
What are the structural and biochemical tolerances of those elements? What portions of
structure dictate function and what portions can be ignored? This thesis work aimed to
disassemble the complicated history of Complex III and start from scratch, building
quinol-cytochrome c function one engineering element at a time.
To design AP6 to have quinol-cytochrome c oxidoreductase activity, the main
elements of these electron transfer reactions in Complex III were extracted and
incorporated into AP6: simple α-helical structure to provide a secure, linear scaffold for
securing cofactors, both hydrophilic and hydrophobic sections of amino acids to promote
interactions with both the membrane and soluble molecules, multiple histidine sites for
heme ligation, and a tryptophan molecule for convenience when determining AP6
concentration.

6.2 Developing a simpler model for Complex III electron transfer
Natural electron transfer chains convert the steep exponential fall-off of electron
tunneling rate with distance to a near linear dependence [7]. Chains of cofactors become
more tolerable to uphill reactions as the chain becomes extended [8]. One of the reasons
heme c1, along with other cofactors in Complex III, is able to accommodate large changes
to its active site residues and redox potential is that Complex III is made up of a large
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chain of cofactors that can compensate for slight changes in the thermodynamics of a
single electron transfer event. Many complicated mechanistic proposals exist that predict
specific structural elements of Complex III active sites that dictate their redox behavior
[1, 9, 10]. Yet when these residues are eliminated, as they were for heme c1 in chapter
two, the equilibrium midpoint potentials of the cofactor are unaffected and enzyme
turnover remains unscathed. Perhaps future experiments and models should begin to
question not what singular engineering elements Complex III relies on for catalytic
efficiency, but instead what groups of things work together collectively to minimize the
costly short-circuits that can be caused by a single electron transfer step.
With no obvious quinone-binding site included in our protein design, AP6
provides clear evidence that a specific quinone-binding site within a membrane protein is
not essential for generating significant quinol-cytochrome c oxidoreductase enzymatic
activity from a heme protein. Proximity of reduced quinol substrates to the hemes in AP6
is accomplished simply by adding an excess of quinone substrate that is free to partition
through the hydrophobic membrane interface. This same reserve of excess quinone
exists in the mitochondrial respiratory chain as the Q-pool. The absence of Qo from
Complex III crystal structures [11-13] suggests that it is mobile [14], diffusing freely
between the Q-pool and its active site. In fact, Qo mobility may help Complex III
regulate unwanted short-circuit reactions. If Qo is only in its active site during forward
turnover, this would be one way of promoting energy transduction over unwanted reverse
electron transfer reactions.
Though the contradictions between various experimental results leaves the
mechanism of the Qo site undefined, that does not necessarily mean that the mechanistic
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suggestions for Complex III turnover need to be overly complex. Qo bifurcation is well
understood, but the reversible and robust nature of Complex III electron transfer dictates
that the high and low potential chains are inextricably linked.

Instead of dividing

Complex III into two separate pathways (Figure 1.3), Complex III can instead be thought
of as a single chain (shown in Figure 6.1) [6, 8], where shifting the equilibrium of one
reaction (i.e. midpoint potential or cofactor distance changes) affects the equilibrium of
all of the remaining reactions in the cofactor chain. Figure 6.1 is drawn to depict
Complex III as a functional monomer, but this simplistic view would still hold true for a
functional Complex III dimer; the two single chain monomers would just be
electronically connected through their bL sites. The distribution of electron equivalents
within Complex III is solely dependent on the rates of each of the reversible partial
reactions, which include all electron tunneling steps, Qo exchange to and from its active
sites, and the distal and proximal movement of FeS.
Recently, Cieluch et al. proposed a similar model based on the results of their
experimental work that modified residues around the R.capsulatus heme c1 binding site to
manipulate heme c1 midpoint potential [6].

In flash experiments without inhibitors

added, they observe that the completion of two Qo turnovers and reduction of Qi leaves
the FeS cluster and c1 saturated with electrons. This reaction is driven to completion
even in Complex III mutants where the midpoint potential of heme c1 is 100 mV lower
than that of the FeS cluster and the electron transfer reaction is uphill.
When the outflow of electrons from the b-chain is blocked by the addition of
antimycin in wild-type Complex III, both b-hemes remain reduced for a significant
amount of time because the low potential chain becomes saturated with electrons. This
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Figure 6.1: A single chain view of Complex III. A similar model was
proposed by Cieluch et al [6]. In this model, Qo is still delivered to its binding
site from a membrane-bound Qpool, but Qo bifurcated oxidation is depicted as
two half-reactions along the same chain rather than considering the high and
low potential chains of Complex III to be two separate electronic paths. Under
these conditions, the equilibrium reactions for each redox step can directly
affect any of the other equilibrium reactions occurring in Complex III.
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effectively shifts the equilibrium at Qo, as the probability for reverse reactions with
reduced bL is greater with the increase in the effective concentration of reduced heme bL.
Likewise, the equilibrium at Qo can also shift as the concentration of reduced FeS cluster
increases, as this substrate can also initiate short-circuit reactions with Qo. The mutants
described by Cieluch et al. shift the Qo equilibrium in this way by manipulating the FeSc1 barrier. The electron distribution in the b-chain of these mutants is directly impacted
by fluctuations in the electron distribution within the c-chain. Therefore, because Qo
reactions can occur reversibly, their work confirms that the bifurcation reaction in
Complex III does not imply that Complex III transfers electrons to two totally
independent redox chains, but that the electrons simply travel in opposite directions from
Qo within the same single chain of cofactors.

6.3 Impact of this work on future experiments
6.3.1 Exploiting Complex III thermodynamics to access Qo states. While
spectroscopically accessing short-circuit states (Figure 1.6) may stay out of experimental
reach for some time to come, stabilizing the green enzyme-substrate and enzyme-product
intermediates will be the key to defining the Qo site mechanism. Chapter five revealed
that manipulating the thermodynamics of a rate-limiting electron transfer step would
modify the reactivity of an enzyme. This concept could conceivably be applied to the Qo
oxidation reaction in order to stabilize two key intermediates – Qo fully reduced and Qo
fully oxidized (green states in Figure 1.6). The following thermodynamic manipulations
could be applied to control Qo site reactivity:

1) replacing ubiquinone with other

quinones and analogues that have either a higher redox midpoint potential, such as
plastoquinone (PQ) and benzoquinones (BQ), or a lower redox potential, such as
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menaquinone (MQ); and 2) using mutants to lower the midpoint potential of FeS or raise
the midpoint potential of heme bL.
For example, by using a FeS mutant with the lowest midpoint potential currently
available in combination with substituting PQ for the native ubiquinone (UQ) at Qo, the
normally unstable reactant state of reduced quinone and oxidized FeS and heme bL will
become thermodynamically stable and experimentally accessible at the lowest pH values
sustainable by Complex III (forest green section of Figure 6.2). Substituting the native
UQ in the Qo site with the higher potential BQ creates this same redox state, and it is

	
  
Figure 6.2: Manipulation of the midpoint potentials of cytochrome bc1 cofactors
allows us to create, at equilibrium, two different intermediate states of the Qo site.
The darker green regions of the graph represent the midpoint potential and pH
combinations that would promote a reduced quinone redox state, where Qo is poised
to transfer electrons to FeS and heme bL. Shown in light green is the fully oxidized Qo
redox state, where FeS and heme bL are both fully reduced. Reprinted with permission
from SpringerLink and the Journal of Bioenergetics and Biomembranes [2].	
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more thermodynamically stable over a much wider pH range (lime green area of Figure
6.2). Stabilizing the other catalytically active state, where Qo is oxidized and both FeS
and heme bL are reduced, requires the opposite strategy (light green of Figure 6.2).
Attaining thermodynamic stability for this state requires replacing the native UQ with
quinones that have intrinsically lower midpoint potential values, such as MQ, and raising
the pH; mutants that raise heme bL midpoint potential can assist the formation of this
redox state.
While mutational changes to FeS midpoint potential have created a wide
thermodynamic range for exploration [15-18], as shown in Figure 6.3, a similar
adjustment of the midpoint of heme bL has proven more challenging [19-21]. There may

Figure 6.3: The range of midpoint potentials of FeS that are available via
characterized mutants are illustrated in brown. So far, heme bL mutations show a more
limited range of midpoint potentials, as shown in blue. Also shown here are the
midpoint potentials for several quinone molecules, including ubiquinone (UQ),
menaquinone (MQ), plastoquinone (PQ), rhodoquinone (RQ), benzoquinone (BQ),
and methanophenazine (MP). As demonstrated in purple, depending on the split of
the two electron transfer couples for the quinone, the maximum amount of
semiquinone generated on an equilibrium timescale will vary. Reprinted with
permission from SpringerLink and the Journal of Bioenergetics and Biomembranes
[2].
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be some hope from preliminary electrostatic calculations that suggest glutamate and
arginine residues outside of the PEWY loop could potentally lower heme bL midpoint
potential [22].
Once equilibrium is attained, these two states can be followed by traditional EPR
or FTIR approaches, since they would no longer be constrained by a quasi-equilibrium
timescale. However, the most important use of this stabilization strategy may be the
potential accessibility of these new equilibria to X-ray crystallography techniques. One
explanation for the absence of bound quinone in the Qo site is that quinone is only bound
in the unstable, catalytically active states [13, 14], a hypothesis that could be confirmed
once these states have been stabilized.
While low midpoint potential FeS mutants are potentially useful in stabilizing the
physiologically active oxidized and reduced quinone catalytic states for leisurely study at
equilibrium, high midpoint potential FeS mutants are potentially useful for facilitating the
creation of pseudo-equilibrium Qo semiquinone states using the light activation method
of Zhang et al [23]. Figure 6.3 shows that as the midpoint potential split between the
oxidizing and reducing couple of the two quinone electron transfers gets larger, and the
equilibrium concentration of semiquinone at Qo becomes extremely small, the quinone
redox couples approach and eventually surpass the midpoint potential values of FeS and
heme bL. By using a mutant of FeS with the highest possible midpoint potential (and
therefore, the greatest oxidizing power), it becomes easier to strip one electron off the
reduced quinone at Qo and leave the other stranded on the semiquinone when the b-chain
is fully reduced. Similarly, the use of higher potential quinones instead of native UQ
should also facilitate the quasi-equilibrium formation of semiquinone at Qo. Instead of
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the pH 9 conditions required for semiquinone formation with native UQ, high midpoint
potential FeS mutants and/or quinone substitutes at lower pH values can be used to verify
that the semiquinone formed is relevant to the Qo catalytic cycle, and also to detail its
engineering in the physiological mechanism.
6.3.2 Maquettes as enzymes – the potential for future designs. Shown in
Figure 6.4 are the uncatalyzed and catalyzed rates for Complex III and the synthetic
enzymes created by this work. One of the goals of protein design is to be able to
understand the engineering of natural proteins enough to design simple model systems
that reproduce natural activity levels. The protein design work contained within this
thesis is the first example of maquette proteins capable of near-natural turnover rates.
The success of the AP6 and HP7 (high potential) designs as Complex III-like enzymes

	
  
	
  
	
  
	
  
Figure 6.4: Uncatalyzed and catalyzed rates for natural and synthetic quinolcytochrome c oxidoreductase proteins. Black arrows for the catalyzed rates represent
natural Complex III and green arrows depict maquettes. The green uncatalyzed arrow
represents direct electron transfer between quinol and cytochrome c. The maquettes in
this work are the first synthetic proteins to demonstrate activity within the range of
natural metabolic enzymes.
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opens the door for studying other aspects of Complex III turnover, including superoxide
production. Complex III and Complex I are both known to be the major sources of
superoxide generation, which can generate acute cellular damage when recovering from
temporary anoxia [24, 25]. It is also known that superoxide generation by Complex III is
closely connected with disruption of mitochondrial membrane permeability, a key step in
programmed apoptosis [26]. The superoxide anion midpoint potential has been estimated
at –140 mV [27], so either heme bL or a SQ/Q couple at Qo are capable of supporting
single electron reduction of oxygen. Whether heme bL [14, 28, 29], SQo [25] or both are
the immediate donors to oxygen to make superoxide is unknown, and has been difficult
to unravel in part because the mechanism at the Qo site remains unknown. Also, another
complication is the generation of the heme bL or SQ reducing states in an oxygen-rich
environment is a state far from chemical equilibrium, and controlling the balance
between reduced SQo or reduced heme bL has been an uncertain task.

Finally,

superoxide generation has almost always been studied with multiple turnover systems of
Complex III, where the redox states of all the Complex III components are rapidly
changing and interrelated, offering little hope of discriminating between the redox states
of heme bL and SQo in a natural system. Studying superoxide production by maquette
proteins yields greater control over the protein system. Instead of trying to unravel
results from a complex chain of redox cofactors, specific cofactors can be incorporated
into the AP6 maquette to isolate their superoxide production.
Heme bL is likely to form an oxyferrous state. This would point towards an inner
sphere electron transfer mechanism for superoxide production at heme bL, where an oxyferrous transition state exists prior to oxygen reduction and release of superoxide.
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Figure 6.5 Cartoon of inner sphere electron transfer between a reduced heme in AP6
and oxygen to form the superoxide anion. AP6 helices (shown in blue) have a
dynamic assembly that permits small ligands, such as oxygen (shown in red), to access
the heme binding site (depicted as green histidine imidizole groups in this diagram)
and form an oxyferrous intermediate state that then reduces oxygen to superoxide.
	
  

Determining the conditions for superoxide production by heme b would be feasible using
AP6. Figure 6.5 depicts how this reaction could take place in AP6. “Leaky” AP6
assembly does allow oxygen to enter the protein core (Figure 3.9) and associate with a
reduced heme cofactor, and should also enable inner sphere electron transfer to form
superoxide.
AP6 can also be modified to study superoxide production by a semiquinone state.
It has been suggested that Qo mobility would be essential to regulating its role in the
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generation of superoxide [30-32]. According to this hypothesis, SQo would reduce
oxygen through an outer sphere electron transfer mechanism when the quinone is present
in the Qo active site. A quinone cofactor could be fixed in a position along the AP6
helix, in the form of a napthoquinone amino acid, in order to study reactions that produce
superoxide in a similar way to reactions that could occur at Qo. However, experiments
prolonging the semiquinone redox state in natural Complex III have been successful at
determining whether or not SQo is capable of superoxide production [32], and should
also be utilized for future studies.

6.4 Conclusion
Assigning a Qo site mechanism remains an elusive goal despite the experimental
progress made since Peter Mitchell’s Q-cycle proposal in 1976 [33, 34]. In order to
differentiate between the mechanisms currently proposed, future studies need to push the
boundaries of current Complex III experiments and generate redox states that are, at
present, too short-lived to be studied spectroscopically.

If these states cannot be

distinguished using natural systems, maquette protein designs that target these quinone
transition states could be studied in order to accept or reject potential Qo mechanisms.
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Appendix
A.1 The Moser Dutton equation – a useful predicting tool
The Dutton laboratory has developed an electron transfer rate expression that
offers a simple way to examine parameters that directly relate to the oxidoreductase
activity of a particular mitochondrial enzyme [1-3]. The Moser-Dutton equation defines
the rate of electron transfer as a function of distance (R), midpoint potential (included in
ΔG°), reorganization energy (λ), and protein packing density (ρ):
log ketexer = 13" (1.2" 0.8# )(R " 3.6)" 3.1

($G o + %)2
%

Equation A.1
!
This equation is based upon an exponential dependence of electron tunneling with

distance through an insulating protein barrier, where the height of the tunneling barrier
depends upon how vacuum-like or how bond-like the intervening protein medium is. An
elementary structure-based estimate that roughly correlates with effective barrier height is
the packing density, which is around 0.76 in a typical protein. Marcus realized that
electron tunneling often has a Gaussian dependence of rate vs. distance [4], with a
maximal possible rate when the driving force (-ΔG° in eV) matches an energetic term
called the reorganization energy for electron tunneling. The reorganization energy can be
thought of as the energy required to move the nuclei of the redox cofactors and their
surroundings from an equilibrium configuration favored when the electron is on the
donor to the equilibrium geometry favored when the electron is on the acceptor, but
constraining the electron to remaining on the donor.
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Marcus’s expression was based on a classical model in which the potential
energy surfaces of the reactant (reduced donor and oxidized acceptor) and product
(oxidized donor and reduced acceptor) were intersecting, parabolic, simple harmonic
oscillator wells, with the reaction coordinate being a generalized one of nuclear
vibration/reorganization that carried the reactant equilibrium geometry into the product
equilibrium geometry. In the Marcus classical view, the vibrations coupled to electron
transfer are all of low enough energy that a non-quantized harmonic oscillator description
is sufficient. Previous studies with photosynthetic reaction centers over a wide range of
cyrogenic temperatures have demonstrated that the Marcus expression is not as
appropriate as an expression that uses vibrations coupled to electron transfer that have an
energy higher than Boltzmann κT at room temperature [5]. The weighted characteristic
frequency of vibration coupled to electron transfer in reaction centers appears to be close
to 0.06 eV, larger than the Boltzmann room temperature energy of about 0.025 eV [6].
Hopfield has previously described an expression that allows this quantized vibrational
frequency but maintains a Gaussian free energy dependence on rate [7]. Although this
characteristic frequency is rather difficult to access experimentally and may vary from
one electron tunneling reaction to another, the generic value appears to give reasonable
estimates of electron transfer rates in many cases. The somewhat broader quantized
version of the Gaussian dependence of rate on free energy gives rise to the 3.1 coefficient
in the room temperature expression of Equation A.1. The corresponding classical Marcus
expression would have a coefficient of 4.2.
Equation A.1 relates to exergonic electron transfer reactions; however, many
biological electron tunneling reactions are uphill. One way to estimate the rate of an
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uphill electron tunneling reaction is to use Equation A.1 to calculate the corresponding
downhill electron transfer of the reverse reaction and then, assuming the forward and
reverse rates are related by a Boltzmann energy term, slow the forward tunneling rate by
an order of magnitude for every 0.06 eV of uphill free energy [3].
Tunneling expressions with fewer parameters are useful in situations where there
is a lack of experimental information. Packing density is the easiest parameter to replace
with a generic value because it rarely has a dominant effect (see Appendix for an
example of this).

The 0.76 packing density typical of a protein leads to the 0.6

coefficient leading the distance term. The next parameter to consider replacing with a
generic term is reorganization energy, both because it is rarely measured with any
precision, and because it does not appear to be engineered in Complex III. 0.7 eV is an
adequate generic value, and leads to a two-parameter expression:

exer
et

log k

(#G o + 0.7)2
= 15" 0.6R " 3.1
0.7
Equation A.2

In order to calculate the electron tunneling rates, user-written programs were

!

constructed in Mathematica 7.0 (Wolfram Research).
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